WO2018030806A1 - Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same - Google Patents
Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same Download PDFInfo
- Publication number
- WO2018030806A1 WO2018030806A1 PCT/KR2017/008676 KR2017008676W WO2018030806A1 WO 2018030806 A1 WO2018030806 A1 WO 2018030806A1 KR 2017008676 W KR2017008676 W KR 2017008676W WO 2018030806 A1 WO2018030806 A1 WO 2018030806A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- region
- cells
- protein
- domain
- mil
- Prior art date
Links
- 239000000833 heterodimer Substances 0.000 title claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 7
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 7
- 102000004127 Cytokines Human genes 0.000 title description 12
- 108090000695 Cytokines Proteins 0.000 title description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 169
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 169
- 230000000694 effects Effects 0.000 claims abstract description 53
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 33
- 235000018102 proteins Nutrition 0.000 claims description 153
- 206010028980 Neoplasm Diseases 0.000 claims description 138
- 108010065805 Interleukin-12 Proteins 0.000 claims description 104
- 102000013462 Interleukin-12 Human genes 0.000 claims description 104
- 229940117681 interleukin-12 Drugs 0.000 claims description 100
- 125000000539 amino acid group Chemical group 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 43
- 230000000975 bioactive effect Effects 0.000 claims description 40
- 238000006467 substitution reaction Methods 0.000 claims description 40
- 108020001507 fusion proteins Proteins 0.000 claims description 39
- 230000035772 mutation Effects 0.000 claims description 39
- 102000037865 fusion proteins Human genes 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 19
- 230000001766 physiological effect Effects 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 5
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 4
- 108010065637 Interleukin-23 Proteins 0.000 claims description 4
- 102000013264 Interleukin-23 Human genes 0.000 claims description 4
- 108010066979 Interleukin-27 Proteins 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 4
- 229940124829 interleukin-23 Drugs 0.000 claims description 4
- 229940127084 other anti-cancer agent Drugs 0.000 claims description 4
- 239000001608 potassium adipate Substances 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000011284 combination treatment Methods 0.000 claims description 2
- 102100033096 Interleukin-17D Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 abstract description 13
- 230000004071 biological effect Effects 0.000 abstract description 8
- 210000004899 c-terminal region Anatomy 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 144
- 201000006747 infectious mononucleosis Diseases 0.000 description 121
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 119
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 119
- 210000001744 T-lymphocyte Anatomy 0.000 description 109
- 241000699670 Mus sp. Species 0.000 description 67
- 241000699666 Mus <mouse, genus> Species 0.000 description 52
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 36
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 36
- 230000001965 increasing effect Effects 0.000 description 35
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 34
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 31
- 210000000952 spleen Anatomy 0.000 description 29
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 28
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 26
- 210000000822 natural killer cell Anatomy 0.000 description 24
- 231100000433 cytotoxic Toxicity 0.000 description 23
- 230000001472 cytotoxic effect Effects 0.000 description 23
- 238000010586 diagram Methods 0.000 description 22
- 210000003743 erythrocyte Anatomy 0.000 description 21
- 210000002865 immune cell Anatomy 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 20
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 20
- 102100037850 Interferon gamma Human genes 0.000 description 19
- 108010074328 Interferon-gamma Proteins 0.000 description 19
- 238000000684 flow cytometry Methods 0.000 description 19
- 210000001165 lymph node Anatomy 0.000 description 19
- 239000000178 monomer Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 238000005406 washing Methods 0.000 description 18
- 229920001213 Polysorbate 20 Polymers 0.000 description 15
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 15
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 15
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 15
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 13
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 13
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 13
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 108090000663 Annexin A1 Proteins 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 101100445364 Mus musculus Eomes gene Proteins 0.000 description 10
- 101100445365 Xenopus laevis eomes gene Proteins 0.000 description 10
- 229940027941 immunoglobulin g Drugs 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 9
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 210000004102 animal cell Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000008004 cell lysis buffer Substances 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 230000001815 facial effect Effects 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 210000004013 groin Anatomy 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 239000000710 homodimer Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 6
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 108091027305 Heteroduplex Proteins 0.000 description 5
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 5
- 102100025305 Integrin alpha-2 Human genes 0.000 description 5
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 5
- 230000004186 co-expression Effects 0.000 description 5
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 4
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229940040731 human interleukin-12 Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 description 2
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940127130 immunocytokine Drugs 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710201246 Eomesodermin Proteins 0.000 description 1
- 102100030751 Eomesodermin homolog Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 description 1
- 101000583935 Homo sapiens CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 1
- 101000912009 Homo sapiens Cyclin-dependent kinase 5 activator 1 Proteins 0.000 description 1
- 101001038346 Homo sapiens GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000980900 Homo sapiens Sororin Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000808126 Homo sapiens Uroplakin-3b Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 description 1
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 description 1
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 description 1
- 101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101000959737 Mus musculus Annexin A1 Proteins 0.000 description 1
- 101000583937 Mus musculus CDK-activating kinase assembly factor MAT1 Proteins 0.000 description 1
- 101001038345 Mus musculus GTP cyclohydrolase 1 feedback regulatory protein Proteins 0.000 description 1
- 101000808124 Mus musculus Uroplakin-3b Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 231100000480 WST assay Toxicity 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Definitions
- the present invention includes a first Fc region and a second Fc region of an antibody (immunoglobulin) heavy chain constant region (Fc) pair,
- Heterodimeric Fc-fused protein having a subunit of a bioactive protein bound to at least one of the N-terminus or C-terminus of the first Fc region and / or the second Fc region.
- the first Fc region and the second Fc region are heterodimeric Fc-fused proteins, characterized in that the CH3 domain is mutated to promote the formation of heterodimers and
- It relates to a pharmaceutical composition comprising the heterodimer-fusion protein.
- Heterodimeric Fc-fused protein according to the present invention is a form and structure in which two or more subunits form a protein complex so that a protein constituting one bioactive protein exists in nature. It can be fused to the antibody heavy chain constant region (Fc), there is an advantage that can maintain the activity as it exists in nature.
- Fc antibody heavy chain constant region
- the half-life of the bioactive protein contained in the heterodimer-fusion protein is significantly increased, and various biological activities in the body are maintained for a long time. There is an advantage that can be sustained.
- heterodimer-fusion protein in which the subunit of the bioactive protein is fused to the N-terminus or C-terminus of the antibody heavy chain constant region heterodimer Fc according to the present invention is expressed after purification, compared with the wild type Fc-based fusion protein. This is easy.
- Immunoglobulin G IgG
- IgM immunoglobulin M
- IgD immunoglobulin D
- IgE immunoglobulin A
- homodimerization between two identical heavy chains is performed by the final domain of the constant region of the antibody (CH3 domain for IgG, IgD, IgA, CH4 domain for IgM, CH2 and CH4 domain for IgE). It is induced by non-covalent interactions between and disulfide bonds between hinge regions.
- Antibody-derived heterodimeric heavy chain constant region (Hterodimeric Fc) technology allows specific non-covalent linkages between the last domain of the constant region (CH3 domain), which contributes significantly to the homologous duplication of earlier spontaneous antibodies (IgG, IgM, IgA, IgD, IgE). Heterogeneous redundancy is preferred, and it is a technique to create heterologous heavy chain invariant regions by engineering them to have a bond that is not preferred or rejected. More specifically, genetic modifications induce mutations in the CH3 domains of two different antibody heavy chains, forming two heterozygotes with very similar structures to naturally occurring antibodies and minimal variation in sequence. (US Patent No. 7,695,936; Korean Patent No. 1,522,954).
- the heterodimeric heavy chain constant region technology is a basic technology for making double antibodies.
- CH3 domain mutants known to induce heterodimers are known to be mostly asymmetric by structure-based rational design of the antibody on the surface of CH3 domain interaction. It was prepared by introducing a red pair of mutations (Spreter Von Kreudenstein et al., 2014).
- the A107 mutant used in the present invention is a high yield heterodimeric heavy chain constant region selected from a human antibody heteroduplex heavy chain constant region library prepared using a yeast cell surface expression system, and a hydrophobic core of the CH3 domain interaction surface. Induces mutations in the conserved and charged amino acids to form complementary hydrophobic bonds (K409W CH3A -D399V / F405T CH3B ) and to form hydrogen bonds (K370E CH3A -E357N CH3B ) to form heterodimers (Choi et al. 2016; Korean Patent Application No. 2015-0142181).
- the native protein complex structure existing in nature is formed as it is, and the activity of the original protein is not only properly expressed. There is no such form of development that can be sustained for a long time.
- heterodimer variants comprising Fc regions from IgG1 as well as other previously reported isotype antibodies such as IgG2, IgG3, and IgG4, Using this, two or more different subunits are formed, and two or more subunits form one protein complex to bind one or more subunits of a protein showing physiological activity to the ends of the Fc region.
- the present invention was completed by developing a novel therapeutic fusion protein in the form of a heterodimeric Fc-fused protein.
- a protein consisting of two or more different subunits in the present invention, wherein the two or more subunits form a protein complex and exhibit physiological activity is preferably Interleukin-12, IL-12) can be used.
- Interleukin-12 increases the activity of immune cells, such as cytotoxic T Lymphocytes (CTL) and natural killer cells (NK), among other immune cells, to directly kill tumors or interferon Inhibits tumorigenesis by activating the immune response in the tumor microenvironment where the immune response is suppressed through the secretion of pro-inflammatory cytokine such as gamma (IFN- ⁇ )
- CTL cytotoxic T Lymphocytes
- NK natural killer cells
- an optional tag for further purification only at the C terminus of one Fc region as shown in FIGS.
- the method of constructing a fusion protein has been used by fusion or by purifying the Fc region and protein separately in high purity.
- this form is not only costly in producing large amounts of protein, but also requires research to further optimize the purification process.
- the problem to be solved in the present invention is a heterozygote-fusion heterozygous form of a new type of antibody heavy chain constant region in which two or more subunits form a protein complex so that the activity of the protein showing physiological activity can be sufficiently maintained for a long time. It is to provide a protein (heterodimeric Fc-fused protein).
- the antibody heavy chain constant region heterodimeric Fc-fused protein according to the present invention has two or more subunits that form a protein complex to form a protein complex that exhibits physiological activity as it exists in nature. By simulating as much as possible, it is a form which can maintain the activity as it exists in nature.
- the half-life of the fusion protein is significantly increased by fusion of the antibody heavy chain constant region, so that various physiological activities in the body can be maintained for a long time.
- the present invention also provides a pharmaceutical composition comprising the antibody heavy chain constant region heterodimeric Fc-fused protein, and a composition and treatment method for the treatment of diseases, in particular cancer, using the same. do.
- the present invention includes a first Fc region and a second Fc region of an antibody (immunoglobulin) heavy chain constant region (Fc) pair,
- heterodimeric Fc-fused protein in which a bioactive protein is bound to at least one of the N-terminus or C-terminus of the first Fc region and / or the second Fc region,
- the physiologically active protein is composed of two or more different subunits (subunit), two or more different subunits (subunit) is characterized in that to form a protein complex (protein complex) to show the physiological activity,
- the first Fc region and the second Fc region provide a heterodimeric Fc-fused protein, characterized in that the CH3 domain is mutated to promote formation of a heterodimeric Fc.
- the present invention also provides a pharmaceutical composition comprising the heterologous-fusion protein and a composition and a method for the treatment of diseases, in particular cancer, using the same.
- 1 (A) to 1 (C) is a diagram showing a strategy for obtaining a fusion protein in the form of monomers and heterodimers using existing wild-type human antibody heavy chain constant region.
- FIG. 1 (D) shows an antibody-cytokine (Immunocytokine) construct by fusing monomeric cytokines to an IgG-type antibody containing a KnoH-in-hole heterodimeric heavy chain constant region (KiH heterodimeric Fc) variant in the existing literature. It is a figure which shows an example.
- Figure 2 (A) and 2 (B) is a diagram showing the monomer and heterodimer fusion protein forms that can be constructed using heterodimeric heavy chain constant region.
- Figure 2 (C) is a diagram showing a heterodimeric fusion protein form in a human antibody of the IgG form containing a heterodimeric heavy chain constant region.
- Figure 3 is a view showing the results of selecting and comparing the sequence of the sequence of each human antibody immunoglobulin G isotype CH3 domain for the production of CH3 domain variants for heterodimer formation by human antibody isotype.
- FIG. 4 is a structural modeling of heterologous heavy double chain constant region variants of the heterologous type having the mutation-induced sequence at the position selected in FIG. 3, and the resulting modeling structure is compared with the wild type IgG1 based A107 mutant and It is a figure which shows the result of an analysis.
- FIG. 5 is a schematic diagram of a vector for expressing heterologous heavy chain constant regions of homologous type constructed by sequence and structural analysis in animal cells. Heterozygous heavy chain constant region variants of each homotype, including the mutated hinge region, were cloned into the vector using the restriction enzyme NotI / HindIII.
- FIG. 6 is a schematic diagram schematically illustrating a scFv-Fc CH3A / Fc CH3B co-expression system for evaluating the degree of heterodimer formation of heteroduplex heavy chain constant region variants due to the duplex size difference of the expressed protein. to be.
- FIG. 7 shows a single-chain antibody fragment (scFv) fused with a single chain antibody fragment (scFv) constructed to evaluate the formation yield of heteroduplex of the antibody heavy chain constant region by the CH3 mutation pair as shown in FIG. 6. .1 Schematic diagram for cloning into vectors.
- Figure 8 is a transient expression of co-transformation in HEK293F cells for evaluating the formation ability of the heteroduplex described in Figure 6 animal cell expression vector introduced with a CH3 mutation pair constructed in accordance with the expression system described in Figures 5 and 7 And, after purification, 5 ⁇ g of protein was isolated on SDS-PAGE under non-reducing conditions for evaluation of heterodimer antibody formation ability, and analyzed by size and combination through Coomasie Blue staining. At this time, wild type Fc using wild type CH3 was used as a negative control.
- FIG. 9 is a diagram showing the result of Western blot using the anti-human IgG-AP conjugated antibody with AP enzyme after protein separation by SDS-PAGE in the same manner as in FIG. 8. .
- Figure 10 (A) is a schematic diagram showing the form of the endogenous interleukin 12 cytokine unfused to the heavy chain constant region, which is a control of the present invention.
- FIG. 10 (B) is a schematic diagram showing the form of a bi-IL-12-Fc fusion protein in which an interleukin 12 cytokine linked with an amino acid linker is fused to a wild-type IgG4 Fc as a comparative example of the present invention.
- FIG. 10 (C) is a schematic diagram showing the form of a mono-IL-12-Fc fusion protein in which the interleukin 12 cytokine is fused with a ⁇ 4-A107 variant made of IgG4 in a heterologous heavy double chain constant region variant of the present invention. to be.
- FIG. 10C are schematic diagrams of vectors for expressing and purifying the fusion protein of the embodiment of the present invention (FIG. 10C) in animal cells.
- Figure 12 is a schematic diagram of a vector for the expression and purification of the fusion protein of the comparative example (Fig. 10 (B) in the animal cell of the present invention.
- FIG. 13 transiently expresses and purifies the animal cell expression vectors of FIGS. 11 (A) and (B) constructed with human and mouse interleukin genes through cotransformation into HEK293F cells, and then amplifies 5 ⁇ g of protein. It is a diagram showing the results of the analysis on the size and combination form by separating on the SDS-PAGE of the condition, Coomasie Blue staining.
- FIG. 14 shows the results of analyzing the fusion proteins of FIG. 13 using size exclusion chromatography.
- FIG. 15 shows peripheral blood immune cells (PHA-activated PBMCs) that induced receptors for IL-12 by treating normal peripheral blood immune cells (normal PBMCs) having no receptor for IL-12 and phytohaemagglutinin (PHA). It is a figure which shows the result of having confirmed the binding ability of the mono-hIL-12-Fc and the wild type bi-hIL-12-Fc which were constructed about with the flow cytometer (FACS).
- PHA-activated PBMCs peripheral blood immune cells
- FACS flow cytometer
- FIG. 16 shows Fc (A107), recombinant human IL-12 (rhIL-12), and bi-hIL-12 in peripheral blood immune cells (PHA-activated PBMCs) inducing receptors for IL-12 by treating PHA, a mitogen.
- Figure showing the results of measuring the cell proliferation according to the concentration-specific treatment of -Fc and mono-hIL-12-Fc through the WST-1 cell proliferation assay.
- FIG. 17 is a view showing the results of measuring the concentration of IFN- ⁇ in the culture supernatant cultured in Figure 16 by ELISA
- FIG. 18 shows normal peripheral blood binding ability of mono-mIL-12-Fc and bi-mIL-12-Fc constructed using the property that mouse IL-12 binds to human IL-12 receptor as well as mouse IL-12 receptor.
- PHA peripheral blood immune cells
- FIG. 19 shows Fc (A107), recombinant mouse IL-12 (rmIL-12), bi-mIL-12-Fc in peripheral blood immune cells (PHA-activated PBMCs) inducing receptors for IL-12 by PHA treatment.
- cell proliferation according to the concentration-specific treatment of mono-mIL-12-Fc is a diagram showing the results measured by the WST-1 cell proliferation assay.
- Figure 20 (A) shows Fc (A107), rmIL-12, bi-mIL-12-Fc and mono-mIL-12-Fc when the tumor size is 100 mm3 in Balb / c mice transplanted with CT26 HER2 / Neu cancer cells It is a diagram showing the results of confirming the change in tumor volume measured during intraperitoneal administration and the size of tumor after lethality of mice at the end of administration.
- FIG. 20 (B) is a graph showing the weight change of the mouse periodically measured during the experiment of FIG. 20 (A).
- FIG. 21 (A) shows bi-mIL-12-Fc and mono-mIL-12-Fc intraperitoneally administered twice a week at the tumor size of 300 mm 3 in CT26 HER2 / Neu transplanted Balb / c mice. It is a figure which measured the change of the tumor volume.
- Figure 21 (B) is a graph showing the change in the volume of the tumor of the individual mice periodically measured in the experimental procedure of Figure 21 (A).
- Figure 21 (C) is a diagram showing the result of confirming the tumor size by killing the mouse 3 days after the last administration of Figure 21 (A).
- Figure 21 (D) is a graph showing the weight change of the mouse periodically measured in the experimental procedure of Figure 21 (A).
- FIG. 21 (E) is a graph of alanine aminotransferase (ALT) which is an indicator of liver toxicity by collecting blood from the facial vein of the mouse on day 1 after the last administration of FIG. 21 (A).
- ALT alanine aminotransferase
- Figure 22 (A) is a graph measuring the increase in the number of CD4 + T cells, CD8 + T cells and NK cells in the spleen after 3 days of the last administration of Figure 21 (A).
- Figure 22 (B) is a view showing the total number of immune cells, CD4 + T cells, CD8 + T cells infiltrated into the tumor after 3 days of the third administration of Figure 21 (A).
- Figure 23 (A) is the result of measuring the IFN-g concentration in the serum isolated by collecting blood from the facial vein of the mouse 24 hours after the last administration of Figure 21 (A) by ELISA.
- FIG. 23 (B) shows bi-mIL-12-Fc and mono-mIL-12 at a molar concentration of 1 ⁇ g rmIL-12 when the tumor size was 300 mm 3 in Balb / c mice transplanted with CT26 HER2 / Neu cancer cells.
- Figure 23 (C) is a graph measuring the cytotoxic effect on CT26 HER2 / Neu cancer cells of cytotoxic T cells isolated from the spleen by killing the mouse 3 days after the last administration of Figure 21 (A).
- Figure 23 (D) shows the cytotoxic effect of cytotoxic T cells isolated from the spleen by killing mice 3 days after the third administration of Figure 21 (A) does not express CT26 HER2 / Neu cancer cells expressing tumor antigens It is a figure analyzed by the flow cytometer using 4T1 cells.
- Figure 23 (E) is a graph measuring the cytotoxic effect on CT26 HER2 / Neu cancer cells of natural killer cells isolated from the spleen by killing the mouse 3 days after the third administration of Figure 21 (A).
- Figure 24 (A) is a graph measuring the number of CD8 + effect T cells isolated from the spleen by lethal mice three days after the last administration of Figure 21 (A).
- Figure 24 (B) is a graph measuring the number of CD8 + effect memory T cells isolated from the spleen by lethal mice three days after the last administration of Figure 21 (A).
- Figure 24 (C) is a graph measuring the number of CD8 + central memory T cells isolated from the spleen by killing the mouse three days after the last administration of Figure 21 (A).
- FIG. 24 (D) shows CT26 HER2 / Neu in Balb / c mice of the same age as those surviving 120 days after administration of 1 ⁇ g mono-IL-12-Fc in FIG. 21 (A). Cancer cells are transplanted to measure the change in the tumor volume of the mouse.
- FIG. 24 (E) shows memory precursor effect cells (KLRG1 - IL-7R + ) and short-lived effect cells (KLRG1) among CD8 + T cells present in the spleen after 3 days of the third administration of FIG. 21 (A).
- + IL-7R - is a diagram of analyzing the percentage of by flow cytometry (flow cytometry).
- FIG. 25 (A) shows the ratio of CD8 + T cells with high expression of T-bet, a transcription factor that inhibits the differentiation of memory cells by killing mice after 3 days of the third administration of FIG. 21 (A). It is a graph analyzed by measuring with a flow cytometer.
- FIG. 25 (B) shows CD8 + T with high expression of Eomes and low expression of T-bet that promote the differentiation of memory cells by killing mice after 3 days of the third administration of FIG. 21 (A). It is a graph analyzed by measuring the percentage of cells by flow cytometry.
- Figure 25 (C) shows CT26 HER2 / Neu Balb / c mice transplanted with cancer cells were intraperitoneally administered with bi-mIL-12-Fc and mono-mIL-12-Fc at a molar concentration of 1 ⁇ g rmIL-12 when the tumor size was 300 mm 3. After time, the expression level of phosphorylated STAT4 in CD8 + T cells isolated from inguinal lymph nodes was measured by flow cytometry.
- Figure 25 (D) is a graph measuring the ratio of CD8 + T cells expressing T-bet inhibiting the differentiation of memory cells in the inguinal lymph nodes 72 hours after one intraperitoneal administration of Figure 25 (C) by flow cytometry.
- FIG. 25 (F) shows that CD8 + T cells isolated from the spleen and inguinal lymph nodes of normal Balb / c mice were stimulated with mono-mIL-12-Fc and bi-mIL-12-Fc cross-linked with an antibody that recognizes Fc.
- the ratio of CD8 + T cells expressing T-bet is a graph measured by flow cytometry.
- FIG. 26 is a schematic diagram showing the differentiation-induced mechanism of memory precursor effector and memory cells induced by mono-mIL-12-Fc and the differentiation-induced mechanism of short-lived effect cells induced by bi-mIL-12-Fc.
- the present invention includes a first Fc region and a second Fc region of an antibody (immunoglobulin) heavy chain constant region (Fc) pair,
- heterodimeric Fc-fused protein in which a bioactive protein is bound to at least one of the N-terminus or C-terminus of the first Fc region and / or the second Fc region,
- the bioactive protein is composed of two or more different subunits (subunit), the two or more different subunits (subunit) is characterized in that the protein complex (protein complex) to form a physiological activity,
- the first Fc region and the second Fc region are for a heterodimeric Fc-fused protein, characterized in that the CH3 domain is mutated to promote formation of a heterodimer.
- Fc region or “heavy chain constant region” means a region including a CH2 domain, a CH3 domain, and a hinge domain derived from an antibody. However, in the case of IgE, it means a region including a CH2 domain, a CH3 domain, a CH4 domain, and a hinge domain.
- the expression “the first Fc region and the second Fc region are mutated to promote the formation of heterodimers” indicates that antibodies present in nature are homodimers in which two Fc regions have the same sequence. (homodimer) form, which causes mutations in some sequences of these Fc regions, thereby promoting the formation of heterodimers through specific non-covalent linkages between the first and second Fc regions and homodimers. It means that the formation of is reduced or preferably mutated so that it hardly occurs.
- the mutations to facilitate the formation of a heterodimer of the first Fc region and the second Fc region according to the present invention are each of the CH3 domains included in the antibody-derived first and second Fc regions. May include mutations that facilitate the formation of this heterodimer.
- heterodimeric Fc or Fc heterodimer includes a first Fc region and a second Fc region, and the first Fc region and the second Fc region are heterodimers. It means a heterodimer, characterized in that the CH3 domain is modified to promote the formation of).
- the first Fc region and the second Fc region in the present invention may be derived from an Fc region selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD, and IgE, respectively, preferably Wherein the first Fc region and the second Fc region are derived from IgG1, IgG2, IgG3, or IgG4, respectively,
- first Fc region and the second Fc region may be characterized in that it is derived from an isotype antibody.
- the mutation of the CH3 domain may be characterized in that it comprises one or more mutations selected from the following group. All mutation positions in the present invention are according to the EU index.
- substitution of the amino acid residue at the K370 position of the CH3 domain of the first Fc region is K370E, K370R, K370M, K370D or K370H,
- substitution of the amino acid residue at the E357 position of the CH3 domain of the second Fc region may be E357N, E357D, E357A, E357I, E357G or E357M, and the substitution of the amino acid residue at the S364 position may be S364T or S364W. .
- substitution of the amino acid residue at the K409 position in the CH3 domain of the first Fc region is K409W
- the substitution of the amino acid residue at the F405 position of the CH3 domain of the second Fc region is F405T
- amino acid residue at the D399 position is The substitution may be characterized as being D399V.
- amino acid residue change such as K370E means that the K at position 370 is changed to E, and all amino acid residue changes in the present invention are used as the same meaning.
- the mutation of the CH3 domain of the first Fc region or the second Fc region may include one or more mutations selected from the following group. (However, the mutation position is according to the EU index)
- the CH3 domains of the first Fc region and the second Fc region as described above may further include the following bonds.
- the mutation of the CH3 domain may be characterized in that it comprises one or more mutations selected from the following group.
- the substitution of the amino acid residue at the K360 position of the CH3 domain of the first Fc region is K360E
- the substitution of the amino acid residue at the E347 position of the CH3 domain of the second Fc region may be E347R.
- Substitution of the amino acid residue at the K409 position of the CH3 domain of the first Fc region is K409W
- Substitution of the amino acid residue at the F405 position of the CH3 domain of the second Fc region is F405T
- Substitution of the amino acid at the D399 position is It may be characterized by the D399V.
- the mutation of the CH3 domain of the first Fc region or the second Fc region may include one or more mutations selected from the following group. (However, the mutation position is according to the EU index)
- the CH3 domains of the first Fc region and the second Fc region as described above may further include the following bonds.
- the CH3 domains included in the antibody-derived first and second Fc regions of the present invention are each
- It may be characterized by having a sequence selected from the group consisting of the amino acid sequence represented by the sequence number of.
- the antibody-derived first Fc region and the second Fc region preferably have a sequence of the CH3 domain described in Table 1 derived from IgG4.
- the subunit of the bioactive protein may be bound only to one of the N-terminus or the C-terminus of the first Fc region or the second Fc region,
- One or more different subunits of one (one) bioactive protein may be respectively bound to the N-terminus or C-terminus of the first Fc region and the second Fc region (FIG. 2 ( B) and FIG. 2 (C)).
- the "subunit of the bioactive protein is bonded only to one terminal of either the N-terminus or the C-terminus of the first Fc region or the second Fc region", the first Fc region or the second Fc One of the subunit (s) of the bioactive protein is bound to either end of the N-terminal or C-terminal end of the region, and the remaining subunit (s) of the bioactive protein are linker-mediated.
- the linker is preferably an amino acid linker, but is not limited thereto.
- the one or more different subunits of one (one) bioactive protein is respectively bonded to each of the N-terminal or C-terminal of the first Fc region and the second Fc region.
- One or more different subunit (s) of the bioactive protein are bound to both the first Fc region and the second Fc region N-terminus, respectively, or the bioactive protein is bound to both the C-terminus of the first Fc region and the second Fc region.
- one or more different subunits of the bioactive protein are respectively bound to both the N-terminus and the C-terminus of the first Fc region and the second Fc region.
- the binding of the terminal of the first Fc region and / or the second Fc region and the subunit of the bioactive protein is genetic fusion. It can be characterized by fused by
- first Fc region and the second Fc region and a subunit of the bioactive protein may be combined in a linker-mediated form.
- the linker is preferably an amino acid linker, but is not limited thereto.
- heterodimeric-fusion protein heterodimeric Fc-fused protein
- the bioactive protein is composed of two or more different subunits, and the two or more different subunits are characterized by forming a (one) protein complex to represent the biological activity.
- the bioactive protein is selected from the group consisting of interleukin 12 (IL-12), interleukin 23 (IL-23), interleukin 27 (IL-27), interleukin 35 (IL-35), and follicle stimulating hormone (FSH).
- IL-12 interleukin 12
- IL-23 interleukin 23
- IL-27 interleukin 27
- IL-35 interleukin 35
- FSH follicle stimulating hormone
- the most preferred bioactive protein according to the present invention is interleukin 12 (IL-12).
- IL-12 Interleukin-12
- IL-12 consists of two subunits of p35 (IL-12A) and p40 (IL-12B), and its bioactive form is p70, a heterodimer of p35 and p40. . In nature, IL-12 must be present in the form of p70, a heterodimer of p35 and p40 in order to have activity.
- the antibody heavy chain constant region heterologous double-fusion protein according to the present invention was implemented.
- At least one subunit of a bioactive protein comprising a first Fc region and a second Fc region according to the present invention, at one or more of the ends of the first and second Fc regions Heterodimeric Fc-fused protein in the antibody heavy chain constant region to which (subunit) is bound,
- At least one subunit (s) constituting one bioactive protein is bound only at either end of the N-terminus or C-terminus of the first Fc region and the second Fc region, and the rest
- the subunit (s) may be linked by a linker
- one or more different subunit (s) of one bioactive protein may be bound to each of the N-terminus and / or C-terminus of the first Fc region and the second Fc region, respectively. have.
- the p35 or p40 subunit is attached to only one terminal of either the N-terminus or the C-terminus of the first Fc region or the second Fc region, and the remaining subunits are the first Fc region or the second Fc region.
- the linker may be linked to a subunit of p35 or p40 that is bound to either the N-terminus or C-terminus of the Fc region to form a heterodimer-fusion protein (FIGS. 2B and 2C). ) Reference).
- any one subunit selected from p35 and p40 is coupled to the N-terminus or C-terminus of the first Fc region, and the other subunit is N-terminus or the C-terminus of the second Fc region.
- Units can form heterodimer-fusion proteins having a combined form (see FIGS. 2 (B) and 2C).
- the physiologically active protein is interleukin 12 (IL-12),
- the p35 or p40 subunit of interleukin 12 is bound to only one of the N-terminus or C-terminus of the first Fc region or the second Fc region, and the remaining subunits are linker-mediated. Form a subunit bound to either the N-terminus or C-terminus of the 1 Fc region or the second Fc region, or
- P35 and p40 subunits of interleukin 12 are respectively bound to the N-terminus or C-terminus of the first Fc region and the second Fc region.
- heterodimeric-fusion protein heterodimeric Fc-fused protein
- the hinge region included in the N-terminus in the first Fc region and the second Fc region may be characterized by mutation of a cysteine residue included in the hinge region.
- the mutation of the cysteine residue in the hinge region is a cysteine residue of the upper hinge region except for the cysteine residue in the core hinge region for heterodimer formation.
- the first Fc region and the second Fc region are included in a whole antibody (whole antibody) form consisting of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD and IgE. can do.
- the "whole antibody form” means the CH2 domain, CH3 domain and hinge region (including CH4 domain in IgE) in the Fc region in the case of IgG, IgA and IgD, in addition to the CH1 domain, VH.
- intact form is meant an antibody comprising a domain, a CL domain and a VL domain.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the antibody heavy chain constant region heterodimer-fusion protein according to the present invention.
- the use of the pharmaceutical composition according to the invention is characterized in that it depends on the use of the bioactive protein contained in the antibody heavy chain constant heterodimer-fusion protein.
- the bioactive protein contained in the antibody heavy chain constant region heterodimer-fusion protein according to the present invention is IL-12 or one or more subunits thereof, and thus the present invention includes IL-12 as a bioactive protein. It provides a pharmaceutical composition for the treatment of cancer comprising an antibody heavy chain constant region heterodimer-fusion protein.
- Cancers treatable with a pharmaceutical composition for treating cancer comprising an antibody heavy chain constant region heterodimer-fusion protein comprising IL-12 or one or more subunits thereof as the bioactive protein include colorectal cancer, melanoma, breast cancer, Pancreatic cancer, kidney cancer, prostate cancer, ovarian cancer, small intestine cancer, esophageal cancer, cervical cancer, lung cancer, lymphoma and hematologic cancer may be selected from the group consisting of, but not limited to.
- compositions according to the invention may additionally include a pharmaceutically acceptable carrier.
- a “pharmaceutically acceptable carrier” is a substance that can be added to the active ingredient to help formulate or stabilize a formulation and does not cause significant deleterious toxic effects on the patient.
- the carrier refers to a carrier or diluent that does not irritate the patient and does not inhibit the biological activity and properties of the heterodimer-fusion protein according to the present invention.
- Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary.
- diluents may be additionally added to formulate injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- Other carriers are described, for example, in Remington's Pharmaceutical Sciences (E. W. Martin).
- compositions include sterile aqueous solutions or dispersions and sterile powders for the preparation of sterile injectable solutions or dispersions for immediate administration.
- the use of such media and agents for pharmaceutically active substances is known in the art.
- the composition is preferably formulated for parenteral injection.
- the compositions may be formulated as solutions, microemulsions, liposomes, or other ordered structures suitable for high drug concentrations.
- the carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyols (eg glycerol, propylene glycol and liquid polyethylene glycols, etc.) and suitable mixtures thereof.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol or sodium chloride in the composition.
- Sterile injectable solutions can be prepared by incorporating the required amount of the heterodimer-fusion protein in an appropriate solvent with one or a combination of ingredients described above as required, followed by sterile microfiltration.
- dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those described above.
- sterile powders for the preparation of sterile injectable solutions some methods of preparation include vacuum drying and freeze-drying (freeze-drying), which produce a powder of the active ingredient and any further desired ingredients from its presterilized-filtered solution. )to be.
- compositions according to the invention may be administered orally or parenterally at dosages and frequencies that may vary depending on the severity of the suffering patient.
- the composition may be administered to the patient as a bolus or by continuous infusion as needed.
- the pharmaceutical compositions according to the invention may be administered rectally, intravenously, subcutaneously, intrauterinely or intratracerebrovascularly, but are not limited thereto.
- the pharmaceutical composition for treating cancer comprising the antibody heavy chain constant region heterodimer-fusion protein comprising IL-12 may be used for combination therapy with other anticancer agents, and the other anticancer agents may be cytotoxic T.
- Cells and / or Natural Killer (NK) cells are preferred, but are not limited to any of the other anticancer agents that can be used in the art and can be used for combination therapy.
- a pharmaceutical composition for treating cancer comprising an antibody heavy chain constant region heterodimer-fusion protein comprising interleukin 12 is used for combination treatment with cytotoxic T cells and / or Natural Killer (NK) cells. Occation,
- ADCC antibody-dependent cell-mediated cytotoxicity
- CTL cytotoxic T lymphocytes
- CTLs cytotoxic T lymphocytes
- the present invention provides a method of treating or preventing a disease comprising administering to a patient in need thereof a pharmaceutical composition comprising an antibody heavy chain constant region heterodimer-fusion protein according to the present invention.
- the treatable or preventable disease depends on the use of the bioactive protein contained in the antibody heavy chain constant heterodimer-fusion protein,
- the present invention provides a method of treating or preventing a patient suffering from cancer selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, prostate cancer, ovarian cancer, small intestine cancer, esophageal cancer, cervical cancer, lung cancer, lymphoma and hematologic cancer.
- Example 1 Design of antibody heavy chain constant region CH3 domain variants for heterodimer formation by human antibody isotype (sequence analysis)
- Figure 3 is a comparison of the sequence of each human antibody immunoglobulin G (IgG) isotype CH3 domains listed.
- IgG human antibody immunoglobulin G
- Each amino acid sequence was identified in the International ImMunoGeneTics information system (IMGT; URL: http://www.imgt.org/).
- IMGT International ImMunoGeneTics information system
- the sequence of G3m (s, t) which has been reported to maintain serum half-life similar to other IgG isotypes among various Gm allotypes, was used (Stapleton NM et al., 2011). ).
- the 409th amino acid sequence unlike IgG1, IgG2, and IgG3, had a sequence conserved in all homotypes at the positions of the other mutations except that it had a different sequence from IgG4 to arginine. It was.
- the position having the same amino acid sequence number was selected as a position for transplanting the A107 mutant pair into an isoform other than IgG1. All amino acid position notations in the present invention follow the EU index (numbering).
- Example 2 Design of antibody heavy chain constant region CH3 domain variants for heterodimer formation by human antibody isotype (structural modeling)
- each mutant shown in FIG. 3 shows whether the mutation can be stably introduced to form a heterodimer.
- Structural modeling uses an online modeling server (URL: https://swissmodel.expasy.org/; Biasini M et al., 2014) as a template of the structure of an already known Immunoglobulin Fc heterodimer variant (PDB ID: 4X98). Predicted through.
- the heterologous mutant A107 heavy chain constant region of each isotype designed through the sequence analysis of Example 1 and the structural analysis of Example 2 is a site-directed mutation performed by a person skilled in the art using synthetic oligonucleotides (Macrogen, Korea) Site-directed mutagenesis) was performed using the NotI / HindIII restriction enzyme in-frame to sequence the signal sequence-hinge-CH2-CH3 to the animal cell expression vector pcDNA3.1 (+) (Invitrogen, USA). Cloning was carried out (see FIG. 5).
- the hinge region used here is a cysteine residue of the upper hinge region except for the cysteine residue in the core hinge region for duplex formation. Substituted with serine residues to prevent formation.
- serine residues to prevent formation.
- only 15 amino acids in the C-terminal region of the central hinge region among the 47 amino acid sequences of the G3m (s, t) allotypes maintain high antibody-specific effect functions (ADCC, CDC) of IgG3. This was confirmed through the literature (Dall'Acqua WF et al., 2006), whereby only 15 amino acids of the C terminus of the sequence shown in FIG. 5 were used.
- Table 2 shows amino acid sequence information of the CH3 region in the wild type and A107 heavy chain constant heterodimeric variant pairs of the present invention.
- Purified antibodies in the scFv-Fc CH3A / Fc CH3B co-expression system were scFv-Fc CH3A homodimer (103 kDa), scFv-Fc CH3A / Fc CH3B heterodimer (78 kDa), Fc CH3B homodimer (53 kDa) Since the molecular weights of) are different, it is possible to compare the degree of heterodimer formation on SDS-PAGE.
- Fc CH3B vector a vector constructed in Example 3 was used, and additionally, scFv was introduced only to the N terminus of Fc CH3A , that is, of pcDNA3.1 (+)-scFv-hinge-CH2-CH3A (scFv-Fc CH3A ). Vectors expressed in the format were cloned.
- Figure 7 shows a schematic diagram of the animal cell expression vector pcDNA3.1 (+)-scFv-hinge-CH2-CH3A (scFv-Fc CH3A ) vector used in the scFv-Fc CH3A / Fc CH3B co-expression system.
- the scFv antibody used is an antibody connecting the VH and VL regions of hAY4a, which is an enhanced version of the humanized antibody hAY4 that specifically binds DR4 (Lee, Park et al. 2010). Cloning was performed using NotI restriction enzyme and BsiWI restriction enzyme located immediately before the hinge region. Wild type Fc was constructed in the same format (scFv-Fc / Fc) as a control for the variants.
- HEK293-F cells Upon 200 mL transfection in a shake flask, HEK293-F cells were seeded in 100 ml of medium at a density of 2.0 ⁇ 10 6 cells / ml and incubated at 150 rpm, 8% CO 2 .
- the resulting heavy and light chain plasmids were diluted in 10 ml FreeStyle 293 expression medium (Invitrogen) with 125 ⁇ g of heavy chain and 125 ⁇ g of light chain in total, 250 ⁇ g (2.5 ⁇ g / ml), with 10 ml of dilute 750 ⁇ g of PEI. The mixture was mixed with the medium (7.5 ⁇ g / ml) and reacted for 10 minutes at room temperature.
- the reacted mixed medium was put in the cells seeded with 100 ml in advance, incubated at 150 rpm and 8% CO 2 for 4 hours, and then the remaining 100 ml of FreeStyle 293 expression medium was added.
- the proteins produced by the cells ie antibodies containing heavy chain constant region variants, are secreted out of the cells by the cells and accumulated in the medium. Therefore, the protein was purified using a protein A Sepharose column (GE healthcare) from the cell culture supernatant collected by centrifugation at 2500 rpm for 20 minutes after cell culture.
- the purification method referred to the standard protocol provided by the Protein A column company, and the purified protein was measured by absorbance at a wavelength of 562 nm using a solution in a BCA protein assay kit (Thermo), and the amount was determined according to the drawn standard curve. was quantified.
- Example 5 5 ⁇ g of the antibody including the heterologous heterologous heterologous heterologous heterologous variant A107 heavy chain in Example 5 was analyzed on SDS-PAGE under 12% non-reducing conditions (FIG. 8).
- the homodimer of the CH3A variant was 103 kD
- the homodimer of the CH3B variant was 53 kD
- the monomer of the CH3B variant was 25 kD
- the heterodimer of the CH3A and CH3B variants was 78 kD.
- Western blots were performed together to determine the extent of more sophisticated homodimers.
- Western blot was performed by separating anti-human IgG-AP conjugated antibody (Sigma) using a method performed by those skilled in the art after separating 0.1 ⁇ g of protein, which is less than SDS-PAGE analysis, in 12% non-reducing conditions ( 9).
- the IgG1 heterodimer into which the wild-type CH3 domain was introduced as a control group showed all homodimers of CH3A / CH3B and CH3A: CH3B heterodimers on SDS-PAGE, whereas IgG2, IgG3, Human antibody isotype A107 heavy chain constant region heterodimer variants incorporating A107 heterodimerization mutations into IgG4 were found to form heterodimers with similar or higher yields than previously reported IgG1-based A107 mutants. .
- the Fc monomer (Half Fc) containing CH3A or CH3B was also observed, which is one of the characteristics of naturally occurring IgG4, and the hinge region (particularly, before the Fab-arm exchange in the blood) occurs. , 228 th serine in the central hinge region). This is due to the characteristic of forming half Fc (Liu H et al., 2012).
- Example 7 Construction of human / mouse IL-12 fusion protein
- the IgG4-based variant ( ⁇ 4-A107) was used.
- Persistent Interleukin 12 fusion protein was constructed.
- Interleukin 12 in nature consists of two different units of p35 monomer (p35; IL-12A) and p40 monomer (p40; IL-12B), which are active by interacting with each other to form heterodimers.
- p35; IL-12A p35 monomer
- p40 monomer p40 monomer
- Has Formation of such heterodimers is achieved by binding more stably with one disulfide bond present between two units. Therefore, we tried to maintain the heterodimer form of cytokines in nature by connecting each monomer to different heterodimeric Fc variants (CH3A or CH3B).
- the heavy chain constant region heterodimeric variant for the construction of the fusion protein was used ⁇ 4-A107 to introduce a heterodimer by introducing an A107 mutation based on IgG4.
- intrinsic functions such as ADCC / CDC of IgG1 in the construction of immunocytokine, which is a fusion form of antibody and cytokine, promote the clearance in vivo.
- the fusion protein was constructed using an IgG4 isotype that shows little function of ADCC / CDC compared to IgG1 (Gillies SD et al., 1999).
- (C) is a fusion protein to which the CH3 mutant pair produced in the present invention is introduced.
- Human interleukin 12 (hIL-12, Uniprot entry name P29460, P29459; SEQ ID NO: 17-18) and mouse interleukin 12 (mIL-12, Uniprot entry name P43432, P43431; SEQ ID NO: 19-20) are both mature except signal sequence Only the DNA sequence encoding the form was amplified and cloned using an NotI / BsiWI restriction enzyme in an in-frame as shown in FIGS. 11 (A) and (B) in an animal cell expression vector containing a ⁇ 4-A107 variant. They were named mono-hIL-12-Fc and mono-mIL-12-Fc, respectively.
- the human / mouse p35 monomer was assigned 15 flexible peptide linkers (G 4 S) 3 Linker between the p35 monomer and the hinge region to allow sufficient interaction with the p40 monomer.
- G 4 S flexible peptide linkers
- bi-hIL-12-Fc and bi-mIL-12- fused with human interleukin 12 (hIL-12) and mouse interleukin 12 (mIL-12) were fused with wild-type IgG4 Fc (wt IgG4).
- Fc was constructed.
- IL-12 which is active only by heteroduplexing
- two units are connected to the 15 peptide linkers, and then the animal cell expression vector containing the ⁇ 4-A107 variant is shown in FIG. 12. It was cloned in-frame using NotI / BsiWI restriction enzyme.
- the comparative example is a fusion protein of the type used in previous studies to make IL-12 fusion proteins (Lisan S. Peng et al., 1999).
- Table 3 shows the amino acid sequences for the mature forms of the monomers of human and mouse interleukin 12 used to construct the fusion protein.
- Example 8 IL-12 fusion protein expression / purification
- the mono-IL-12-Fc fusion protein of FIG. 10C shows 1: 1 ratio of expression vectors of human / mouse IL-12.p40- ⁇ 4-A107A and human / mouse IL-12.p35- ⁇ 4-A107B. It was expressed / purified in the same manner as in Example 5.
- the bi-IL-12-Fc fusion protein of FIG. 10 (B) was expressed / purified via a single transfection of the human / mouse scIL-12-IgG4 Fc (wt) expression vector. All fusion proteins were expressed / purified at a similar level of 12-13 mg per 100 ml HEK293F cell culture.
- SEC 14 is a result of size-exclusion chromatography (SEC) of the fusion proteins. Some polymers were observed in the Mono-hIL-12-Fc fusion protein.
- Example 8 The binding ability of the mono-hIL-12-Fc expressed and purified in Example 8 to the IL-12 receptor was compared with bi-hIL-12-Fc.
- FIG. 15 shows the result of confirming that the mono-hIL-12-Fc constructed as compared with bi-hIL-12-Fc showed binding ability to the IL-12 receptor by FACS Calibur (BD Biosciences).
- PBMC immune cells
- PHA Sigma-Aldrich
- T and NK cells were treated for 72 h to stimulate T and NK cells.
- PHA treatment has been reported to express IL-12 receptors on T cells and NK cells as the immune cells divide.
- 1 ⁇ 10 6 cells / ml of PBMC was added to RPMI1640 medium containing 10% FBS, and PHA was added at a concentration of 10 ⁇ g / ml as a mitogen, followed by incubation for 72 hours at 37 degrees and 5% CO 2 incubator.
- Normal PBMC and PHA activated PBMC were washed with cold PBS (pH 7.4) and 5 ⁇ 10 5 cells were prepared for each sample.
- Fc (A107), bi-hIL-12-Fc and mono-hIL-12-Fc were added at a concentration of 1 ⁇ M, reacted at 4 ° C. for 30 minutes, and washed with cold PBS (pH 7.4).
- FITC fluorescence-linked secondary antibody Sigma-Aldrich
- FACS Calibur BD Bioscience
- bi-hIL-12-Fc and mono-hIL-12-Fc did not bind to normal PBMCs that did not express IL-12 receptors, but only to PBMCs that were activated by PHA and expressed IL-12 receptors. Therefore, the binding capacity of mono-hIL-12-Fc to IL-12 receptor was confirmed to be the same as bi-hIL-12-Fc.
- IL-12 recombinant human IL-12
- FIG. 16 shows WST-1 cell proliferation test results confirming cell proliferation ability by Fc (A107), rhIL-12, bi-hIL-12-Fc and mono-hIL-12-Fc in PHA-activated PBMCs.
- PBMC PBMC (2 ⁇ 10 4, 50 ⁇ l) activated with PHA was added to 96-well plate (SPL, Korea) and serially diluted with RPMI1640 medium containing 10% FBS as in Example 9.
- Example 11 Evaluation of the ability to induce IFN- ⁇ secretion of mono-hIL-12-Fc fusion protein against PBMC
- FIG. 17 shows ELISA results of measuring the amount of IFN- ⁇ secretion by Fc (A107), rhIL-12, bi-hIL-12-Fc and mono-hIL-12-Fc in PHA activated PBMC.
- Example 10 in order to measure IFN- ⁇ concentration in cell culture cultured for 72 hours in Example 10, a human IFN- ⁇ capture antibody (Thermo Fisher Scientific) was placed in a 96-well plate (Thermo Fisher Scientific, Korea) for ELISA. After coating for 12 hours, washed with PBST (PBS with 0.1% Tween-20), 1% BSA (PBS with 1% bovine serum albumin) was added and blocked for 1 hour at room temperature. After washing with PBST (PBS with 0.1% Tween-20), the culture cultured in Example 2 was diluted 5 times with 1% BSA, added 100 ⁇ l, and then reacted at room temperature for 2 hours.
- PBST PBS with 0.1% Tween-20
- BSA PBS with 1% bovine serum albumin
- mono-hIL-12-Fc showed that IFN- ⁇ secretion ability to PBMC is similar or higher than rhIL-12.
- Example 8 The binding ability of the mono-mIL-12-Fc expressed and purified in Example 8 to the IL-12 receptor was compared with bi-mIL-12-Fc.
- FIG. 18 is a flow cytometry result confirming that mono-mIL-12-Fc constructed as compared with bi-mIL-12-Fc shows binding ability to IL-12 receptor.
- mouse IL-12 was reported to bind not only mouse IL-12 receptor but also human IL-12 receptor, and analyzed in the same manner as in Example 9.
- bi-mIL-12-Fc and mono-mIL-12-Fc did not bind to normal PBMCs that did not express IL-12 receptors, but only to PBMCs that were activated by PHA and expressed IL-12 receptors. Therefore, the binding capacity of mono-mIL-12-Fc to IL-12 receptor was confirmed to be the same as bi-mIL-12-Fc.
- WST-1 confirmed the cell proliferation ability by Fc (A107), recombinant mouse IL-12 (rmIL-12), bi-mIL-12-Fc and mono-mIL-12-Fc in PHA activated PBMC Cell proliferation assay results.
- Example 13 cell proliferation in PBMCs activated with PHA of mono-mIL-12-Fc was confirmed. It was confirmed whether the effect of mono-mIL-12-Fc is the same in vivo.
- 20 (A) and 20 (B) show the results of measuring tumor growth inhibitory activity of mono-mIL-12-Fc in 100 mm 3 tumors.
- mice hair of 4 week old female Balb / c mice (NARA Biotech, Korea) was removed with a razor and CT26 HER2 / Neu colorectal cancer cells (1 ⁇ 10 6 cells / mouse) were diluted in 150 ⁇ L PBS and transplanted into the mouse subcutaneous. It was.
- Figure 21 (A), 21 (B) and 21 (C) is the result of measuring the tumor growth inhibitory activity in mice in vivo of mono-mIL-12-Fc administered at different concentrations in mice with 300 mm 3 tumor size to be.
- mice hair of 4 week old female Balb / c mice (NARA Biotech, Korea) was removed with a razor and CT26 HER2 / Neu colorectal cancer cells (1 ⁇ 10 6 cells / mouse) were diluted in 150 ⁇ L PBS and transplanted into the mouse subcutaneous. It was.
- bi-IL-12-Fc was mono-mIL-12-Fc at a molar concentration of 1 ⁇ g IL-12 or less even for large tumors. Compared with that, the effect of inhibiting tumor growth was significantly higher.
- the same molar concentration of mono-mIL-12-Fc was effective in removing tumors in 40% of mice.
- 73% of the tumors were cleared by only 5 doses of mono-mIL-12-Fc at a concentration of 0.5 ⁇ g IL-12 where bi-mIL-12-Fc did not remove tumors.
- Figure 21 (D) is the result of measuring the weight change in vivo toxicity of mono-mIL-12-Fc administered by concentration.
- the weight of the mice administered as shown in Figure 21 (A) was measured twice a week to observe the weight loss.
- the weight of the tumor was increased as the tumor size increased, but it was confirmed that there was no weight loss in the mice administered with all concentrations of bi-mIL-12-Fc and mono-mIL-12-Fc. Therefore, mono-mIL-12-Fc was not considered to be in vivo toxic to induce weight loss.
- Figure 21 (D) is the result of measuring alanine aminotransferase (ALT) which is an indicator of liver toxicity.
- blood was collected from the facial vein at 24 hours of the last administration in the mouse of FIG. 21 (A). Blood was left at room temperature for 2 hours to induce coagulation, and then centrifuged at 8000 rpm for 10 minutes to recover serum from the upper layer.
- blood was collected from the facial vein of the mouse 24 hours after the last IL-12-Fc fusion protein administration. The blood was left at room temperature for 2 hours to induce coagulation, and then centrifuged at 8000 rpm for 10 minutes to recover serum from the upper layer.
- ALT measurement substrate solution (alanine and ⁇ -ketoglutarate mixed solution) was taken in a 15 ml test tube and incubated in a 37 ° C constant temperature water bath for 5 minutes.
- the mice transplanted with the tumor were treated with bi-mIL-12-Fc and mono-mIL-12-Fc, and blood samples were collected by diluting the serum 10-fold and adding 200 ⁇ l and shaking. Incubate for 30 minutes in a water bath. 1 ml of color solution (2,4-dinitrophenyl-1-hydrazone) was added to the test tube taken out of the constant temperature water bath, followed by mixing at room temperature for 20 minutes.
- Example 16 Evaluation of immune cell proliferation induction capacity of mono-mIL-12-Fc in vivo
- Figure 22 (A) is the result of confirming the increase in the number of CD4 + T cells, CD8 + T cells and NK cells in the spleen after 3 days of the last administration of Figure 21 (A).
- the mouse spleen was extracted at 34 days after tumor transplantation, pulverized with a wire mesh in Petri dishes and washed with 10 ml of medium containing 2% FBS. Thereafter, 1 ml of red blood cell lysis buffer was added to erythrocytes, and red blood cells were lysed and washed with PBS to prepare splenocyte turbidity, and the number of cells was counted with a hemocytometer. Spleen lymphocytes were stained at 4 ° C. for 30 minutes with antibodies recognizing CD45, CD3, CD4, CD8 and CD49b bound to APC, FITC, PE or PE-cy5 and washed with cold PBS (pH 7.4).
- CD45 + CD3 + CD4 + cell populations CD45 + CD3 + CD8 + cell populations
- CD45 + CD3 - CD49b + cell populations CD4 + T cells, CD8 + T cells, and NK cells.
- the ratio of total splenocytes was calculated and the number of CD4 + T cells, CD8 + T cells and NK cells increased after mono-mIL-12-Fc administration by multiplying the number of cells counted with hemocytometer. .
- mono-mIL-12-Fc infiltrated tumors based on the report that the increase in the number of CD4 + T cells and CD8 + T cells, which are adaptive immune cells infiltrated into tumors, is important (Schreiber et al., 2011). It was analyzed whether the number of adaptive immune cells increased. When 6 mono-mIL-12-Fc were administered to a large number of mice without tumors, the number of immune cells infiltrated into the tumors of mice after 3 administrations was analyzed.
- Figure 22 (B) is the result showing the total number of immune cells, CD4 + T cells and CD8 + T cells infiltrated into the tumor by 3 days after the third administration of the 21 (A).
- the tumor of the mouse was extracted and weighed on the 24th day of tumor transplantation, and then pulverized using a wire mesh and collagenase (100 ⁇ g / ml) in Petri dish, followed by 2% FBS. 10 ml of the medium containing the was added and centrifuged at 50 g for 5 minutes to remove the parenchyma. Thereafter, 1 ml of red blood cell lysis buffer was added to erythrocytes, and red blood cells were lysed, washed with PBS to prepare a cell suspension, and the number of cells was counted with a hemocytometer. Cells isolated from tumors were stained at 4 ° C.
- CD45 + T cells and tumor infiltrating CD8 + T cells were defined.
- bi-mIL-12-Fc and mono-mIL-12-Fc showed the number of total immune cells, CD4 + T cells, and CD8 + T cells infiltrating tumors in tumor-transplanted mice. It can be confirmed that increased.
- Mono-mIL-12-Fc increased the number of total immune cells, CD4 + T cells, and CD8 + T cells infiltrated tumors more significantly than bi-mIL-12-Fc. Therefore, mono-mIL-12-Fc significantly increased the number of CD4 + T cells and CD8 + T cells infiltrating tumors than bi-mIL-12-Fc.
- Example 17 Evaluation of cytokine secretion and cytotoxicity function of mono-mIL-12-Fc in vivo immune cells
- IL-12 is known to inhibit the growth of cancer cells by increasing IFN-g secretion of T cells and NK cells (Trinchieri, 2003). IL-12 also has an anticancer effect by enhancing direct cytotoxic effects on cancer cells of cytotoxic T cells and natural killer cells. Therefore, we analyzed whether the anti-cancer effect of Mono-IL-12-Fc was due to the increase of serum IFN-g concentration and the direct cytotoxic effect of cytotoxic T cells and natural killer cells on cancer cells.
- Figure 23 (A) is the result of measuring the IFN-g concentration in the serum isolated by collecting blood from the facial vein of the mouse 24 hours after the last administration of Figure 21 (A) by ELISA.
- FIG. 20 blood was collected from the facial vein of the mouse 24 hours after the last mIL-12-Fc fusion protein administration in FIG. 20 (A).
- the blood was left at room temperature for 2 hours to induce coagulation, and then centrifuged at 8000 rpm for 10 minutes to recover serum from the upper layer.
- a mouse IFN- ⁇ capture antibody was coated in a 96-well plate for ELISA (Thermo Fisher Scientific) for 12 hours, followed by washing with PBST (PBS with 0.1% Tween-20).
- 1% BSA PBS with 1% bovine serum albumin
- bi-mIL-12-Fc was not capable of inducing IFN- ⁇ secretion by NK cells and T cells, and thus, bi-mIL-12-Fc was administered in FIG. 23 (A).
- mono-mIL-12-Fc and bi-mIL-12-Fc were administered only once, and then blood IFN- ⁇ levels were measured over time.
- FIG. 23 (B) shows IFN- ⁇ in serum by time after intraperitoneal administration of bi-mIL-12-Fc and mono-mIL-12-Fc to Balb / c mice transplanted with CT26 HER2 / Ne colorectal cancer cells. Concentration was measured by ELISA.
- a mouse IFN- ⁇ capture antibody was coated in a 96-well plate for ELISA (Thermo Fisher Scientific) for 12 hours, followed by washing with PBST (PBS with 0.1% Tween-20).
- PBST PBS with 0.1% Tween-20
- 1% BSA PBS with 1% bovine serum albumin
- the serum was diluted 10-fold with 1% BSA and reacted at room temperature for 2 hours.
- biotin-coupled mouse IFN- ⁇ detection antibody was bound for 1 hour at room temperature.
- the bi-mIL-12-Fc-administered group showed a similar concentration of IFN- ⁇ in the blood to the mono-mIL-12-Fc-treated group until day 5 in the tumor-grafted mice. There was no inherent deficiency in the ability of -Fc to induce the secretion of IFN- ⁇ in effector cells.
- Figure 23 (C) is a graph measuring the cytotoxic effect on CT26 HER2 / Neu cancer cells of cytotoxic T cells isolated from the spleen by killing the mouse 3 days after the last administration of Figure 21 (A).
- mice 72 hours after the last cytokine administration in FIG. 21 (A), mice were killed and spleens were removed and spleens and PBS were put into a 60 mm dish containing 70 micron mesh and ground.
- the cells obtained by centrifugation were lysed with red blood cell hemolysis buffer, and then washed with PBS and washed with PBS, an APC conjugated antibody that recognizes CD3 (Thermo Fisher Scientific), and a PE conjugated antibody that recognizes CD8 (Thermo Fisher Scientific).
- the reaction was carried out for 30 minutes at 4 °C. After washing with PBS, cytotoxic T cells (CD3 + CD8 + ) were isolated by FACS Aria III (BD biosciences, Korea).
- CT26 HER2 / Neu cancer cells were stained with calcein AM (Thermo Fisher Scientific Inc., 10 ⁇ M). After CT26 HER2 / Neu cancer cells (2 ⁇ 10 6 ) were suspended in 2 ml of DPBS, 2 ⁇ l of calcein AM (10 mM) was added and mixed, followed by reaction for 45 minutes at 5% CO 2 and 37 ° C.
- a RPMI1640 with 10% FBS was added 10 ml into three times, washed, and then put into a 2 ⁇ 10 4 cells per well in a 96-well plate cytotoxic T cells (1 ⁇ 10 5/100 ⁇ l / well) into each 5 % CO 2 , incubated for 4 hours at 37 °C incubator.
- Live CT26 HER2 / Neu cancer cells that fluoresce green and dead CT26 HER2 / Neu cancer cells that do not fluoresce green were analyzed by flow cytometry to express the cytotoxic effect of cytotoxic T cells in percentage.
- Cytotoxic T cells isolated from tumor-grafted mice treated with Mono-mIL-12-Fc were cytotoxic T cells isolated from tumor-grafted mice administered bi-mIL-12-Fc or cytotoxic T cells isolated from the control group.
- the cytotoxic effect on CT26 HER2 / Neu cancer cells, which are more target cells, was higher, and the tumor suppression effect of mono-mIL-12-Fc was a direct cytotoxic effect of cancer cells by some cytotoxic T cells.
- Figure 23 (D) is the third dose of Figure 21 (A) to determine whether the cytotoxic effect of cytotoxic T cells enhanced by administration of mono-IL-12-Fc in tumor-grafted mice is cancer antigen specific. Three days later, the cytotoxic effect of cytotoxic T cells isolated from the spleen by lethal mice was measured using CT26 HER2 / Neu cancer cells expressing tumor antigen and 4T1 cells not expressing tumor antigen.
- mice 72 hours after the three-time administration of mono-IL-12-Fc in FIG. 20 (A), mice were killed and spleens were removed, and spleen and PBS were placed in a 60 mm dish containing 70 micron mesh. Pulverized. Cytotoxic T target cells in CT26 HER2 / Neu tumor cells and cytotoxic T Target cells 4T1 cytotoxic effect in the same way as FIG. 21 (C) to measure CT26 HER2 / Neu cancer with 4T1 tumor cells to a non-cellular in the cell Were stained with calcein AM (Thermo Fisher Scientific Inc., 10 ⁇ ).
- calcein AM Thermo Fisher Scientific Inc., 10 ⁇
- the RPMI1640 with 10% FBS was added 10 ml into three times, washed, and then put into a 2 ⁇ 10 4 cells per well in a 96-well plate cytotoxic T cells (1 ⁇ 10 5/100 ⁇ l / well) into each 5 % CO 2 , incubated for 4 hours at 37 °C incubator.
- Green Fluorescent Live CT26 HER2 / Neu Dead CT26 HER2 / Neu with no green fluorescence with cancer cells or 4T1 cancer cells Cancer cells or 4T1 cancer cells were analyzed by flow cytometry to express the cytotoxic effects of cytotoxic T cells in percentage. As a result, it was confirmed that the cytotoxic effect of the cytotoxic T cells enhanced by the administration of mono-mIL-12-Fc was target cell specific.
- Figure 23 (E) is a result of measuring the cytotoxic effect on CT26 HER2 / Neu cancer cells of natural killer cells isolated from the spleen by killing the mouse 3 days after the third administration of Figure 21 (A).
- mice were killed and spleens were removed, and spleens and PBS were put in a 60 mm dish containing 70 micron mesh and ground.
- the cells obtained by centrifugation were lysed with red blood cell hemolysis buffer, washed with PBS, and washed with PBS, and APC-bound antibody (Thermo Fisher Scientific) that recognizes CD3 and PE-bound antibody (Thermo Fisher Scientific) that recognizes CD49b.
- the reaction was carried out for 30 minutes at 4 °C. After washing with PBS, natural killer cells (CD3 - CD49b + ) were separated by FACS Aria III (BD biosciences, Korea).
- CT26 HER2 / Neu Cancer cells were stained with calcein AM (Thermo Fisher Scientific Inc., 10 ⁇ M) to measure the cytotoxicity of the target cells in CT26 HER2 / Neu cancer cells of NK cells.
- CT26 HER2 / Neu cancer cells (2 ⁇ 10 6 ) were suspended in 2 ml of DPBS, 2 ⁇ l of calcein AM (10 mM) were mixed and allowed to react for 45 minutes at 5% CO 2 , 37 ° C.
- a RPMI1640 with 10% FBS was added 10 ml into three by three times, and then each well in a 96-well plate into a 2 ⁇ 10 4 cells into natural killer cells (1 ⁇ 10 5/100 ⁇ l / well) , respectively 5% Incubated for 4 hours in a CO 2 , 37 °C incubator.
- Live CT26 HER2 / Neu cancer cells that fluoresce green and dead CT26 HER2 / Neu cancer cells that do not fluoresce green were analyzed by flow cytometry to express the cytotoxic effect of natural killer cells in percentage.
- Natural killer cells isolated from tumor-grafted mice treated with Mono-mIL-12-Fc were more targeted than natural killer cells isolated from bi-mIL-12-Fc-treated mice or with cytotoxic T cells isolated from the control group.
- the cytotoxic effect on CT26 HER2 / Neu cancer cells, which are the cells, was high, and the tumor suppression effect of mono-mIL-12-Fc was a direct cytotoxic effect of cancer cells by some natural killer cells.
- the generation of adaptive immunity in tumor-grafted mice is assessed by effector memory CD8 + T cells and memory CD8 + T cell formation.
- Tumor elimination effect by Mono-mIL-12-Fc was determined by the effect memory CD8 + T cells and memory CD8 + T cell formation.
- 24 (A), 24 (B) and 24 (C) show effect CD8 + T cells, effect memory CD8 + T cells and memory CD8 generated when mono-mIL-12-Fc was administered to mice with tumors, respectively. + The result of measuring the number of T cells.
- the mouse spleen was extracted at 34 days after tumor transplantation, pulverized using a wire mesh in Petri dishes, washed with 10 ml of medium containing 2% FBS, and then erythrocyte hemolysis buffer 1 ml of red blood cell lysis buffer was added to erythrocytes, and then washed with PBS to prepare a splenocyte suspension, and the number of cells was counted with a hemocytometer.
- Splenocytes were stained at 4 ° C. for 30 minutes with antibodies recognizing CD3, CD8, CD62L and IL-7 receptor (IL-7R) bound to PE-cy5, PE, FITC or APC, and cold stained with PBS (pH 7.4).
- CD3 + CD8 + CD62L low IL-7R low Cell groups CD3 + CD8 + CD62L low IL-7R hi cell populations and CD3 + CD8 + CD62L hi IL-7R hi cell populations were defined as effect CD8 + T cells, effect memory CD8 + T cells and memory CD8 + T cells, respectively.
- the number of effect CD8 + T cells, effect memory CD8 + T cells, and memory CD8 + T cells after mono-mIL-12-Fc administration was analyzed by multiplying the number of cells counted by hemocytometer. .
- mono-mIL-12-Fc increased the number of effect memory CD8 + T cells and memory CD8 + T cells in a tumor-grafted mouse compared with the control group.
- bi-mIL-12-Fc increased the number of effect memory CD8 + T cells and memory CD8 + T cells only in the group administered with a molar concentration such as 0.5 ⁇ g IL-12, and the molar like 1 ⁇ g IL-12.
- the concentration group did not increase the number of effect memory CD8 + T cells and memory CD8 + T cells. Therefore, mono-mIL-12-Fc significantly increased the number of effect memory CD8 + T cells and memory CD8 + T cells than bi-mIL-12-Fc.
- Figure 24 (D) is in the mice survived 120 days after the administration in 21 (A) to FIG 1 ⁇ g mono-IL-12-Fc CT26 HER2 / Neu Cancer cells are transplanted to measure the change in the tumor volume of the mouse.
- FIG. 21 (A) the last 1 ⁇ g mono-IL-12- was applied to female Balb / c mice (NARA Biotech, Korea) that matched the age of the surviving mice after administration of 1 ⁇ g mono-IL-12-Fc.
- the hair of the mouse was removed with a razor and CT26 HER2 / Neu cells (1 ⁇ 10 6 cells / mouse) were transplanted into the mouse subcutaneously diluted in 150 ⁇ L PBS.
- additional 1 ⁇ g mono-IL-12-Fc of the measurement without the administration of the tumor twice a week, and the volume (V) of the tumor was calculated as V L x W 2/2.
- bi-mIL-12-Fc was compared with mono-mIL-12-Fc in the number of spleen CD8 + T cells, the number of effect memory CD8 + T cells, and central memory CD8 in mice transplanted with tumors.
- the effect of increasing the number of + T cells was observed to be low.
- the effect CD8 + T cells are partially differentiated into memory CD8 + T cells through memory precursor effector cells (MPEC) and are mostly short-lived. It has been reported to die as short-lived effector cells (SLEC).
- MPEC memory precursor effector cells
- SLEC short-lived effector cells
- FIG. 24 (E) shows memory precursor effect cells (KLRG1 - IL-7R + ) and short-lived effect cells (KLRG1) among CD8 + T cells present in the spleen after 3 days of the third administration of FIG. 21 (A). + IL-7R - an analysis of the rate of).
- the mouse spleen was extracted on the 24th day of tumor transplantation, and then pulverized using a wire mesh in Petri dishes and washed with 10 ml of medium containing 2% FBS. Thereafter, 1 ml of red blood cell lysis buffer was added to lyse red blood cells, and then washed with PBS to prepare a cell suspension. Splenocytes were stained at 4 ° C. for 30 minutes with antibodies recognizing CD3, CD8, KLRG1 and IL-7 receptor (IL-7R) bound to PE-cy5, PE, FITC or APC, and cold stained with PBS (pH 7.4).
- IL-7R IL-7 receptor
- bi-mIL-12-Fc did not increase the proportion of memory precursor cells compared to the control group, but rather increased the number of short-lived cells. Therefore, mono-mIL-12-Fc promoted the production of memory precursor cells more than bi-mIL-12-Fc and significantly increased the number of effect memory CD8 + T cells and memory CD8 + T cells, resulting in a higher tumor removal effect. Confirmed.
- Example 20 Evaluation of the Effect of Mono-mIL-12-Fc on the Expression of Transcription Factors Related to Memory Cell Differentiation Induction
- T-bet a transcription factor that differentiates CD8 + T cells into short-lived effect cells
- Eomes eomesodermin
- 25 (A) and 25 (B) show the percentage of CD8 + T cells with high expression of T-bet that inhibits the differentiation of memory cells in the spleen by killing mice 3 days after the third dose of FIG. 21 (A). This is the result of measuring the ratio of CD8 + T cells with high expression of Eomes and low expression of T-bet that promotes the differentiation of memory cells by flow cytometry.
- the mouse spleen was extracted on the 24th day of tumor transplantation, and then pulverized using a wire mesh in Petri dishes and washed with 10 ml of medium containing 2% FBS. Thereafter, 1 ml of red blood cell lysis buffer was added to lyse red blood cells, and then washed with PBS to prepare a cell suspension. Splenocytes were stained with PE-cy5 or FITC-coupled CD3 and CD8 antibodies for 30 minutes at 4 ° C, washed with cold PBS (pH 7.4), and stained with transcription factor Foxp3 / Transcription Factor.
- the cells were fixed and permeabilized using Staining Buffer Set (Thermo Fisher Scientific), and then stained for 30 minutes at 4 ° C. with an antibody recognizing T-bet or Eomes bound to PE or efluor 660.
- Permeabilization buffer was added and analyzed by flow cytometry FACS Calibur (BD Bioscience) and Flow jo (Thermo Fisher Scientific). Each sample was analyzed by dot plot to analyze the ratio of CD3 + CD8 + T-bet high cell population and CD3 + CD8 + Eomes + T-bet low cell population.
- mono-mIL-12-Fc reduced the proportion of CD3 + CD8 + T-bet high cell populations in a tumor-dependent mouse compared to the control group, and decreased the concentration of CD3 + CD8 + Eomes + T-bet low cells. It was confirmed that the ratio was increased.
- bi-mIL-12-Fc decreased the proportion of CD3 + CD8 + T-bet high cell population only in the group administered with 0.5 ⁇ g IL-12, and CD3 + CD8 + Eomes + T-bet low
- the percentage of cell population was increased, and in the group administered with a molar concentration such as 1 ⁇ g IL-12, the percentage of CD3 + CD8 + T-bet high cell population was decreased or the percentage of CD3 + CD8 + Eomes + T-bet low cell population was decreased. There was no increasing effect.
- mono-mIL-12-Fc reduces the proportion of CD3 + CD8 + T-bet high cell population and increases the ratio of CD3 + CD8 + Eomes + T-bet low cell population than bi-mIL-12-Fc.
- the number of CD8 + T cells and memory CD8 + T cells was significantly increased to confirm that the tumor removal effect was high.
- CD8 + T cells when stimulated with inflammatory cytokines such as IL-12 in the presence of T cell receptor and co-stimulatory signals, increase phosphorylation of STAT4, and phosphorylated STAT4 (pSTAT4) migrates inside the nucleus to the T-bet enhancer. It is known to bind to increase expression of T-bet. Therefore, when 8 ⁇ g IL-12 at a molar concentration of bi-mIL-12-Fc is administered, CD8 + T cells are differentiated into short-lived cells.
- Fc administration increased the expression of pSTAT4 and T-bet when CD8 + T cells were activated in the groin lymph nodes, the tumor draining lymph nodes of mice transplanted with tumors than mono-mIL-12-Fc. Cognitive was measured.
- Figure 25 (C) shows the molar concentrations of bi-mIL-12-Fc and mono-mIL-12-Fc at the same molar concentration of 1 ⁇ g rmIL-12 when the tumor size was 300 mm 3 in CT26 HER2 / Ne transplanted Balb / c mice.
- the expression level of phosphorylated STAT4 in CD8 + T cells isolated from inguinal lymph nodes 24 hours after one intraperitoneal administration was measured by flow cytometry.
- Inguinal lymph node cells were stained with PE-cy5 or FITC-coupled CD3 and CD8 antibodies for 30 minutes at 4 ° C, washed with cold PBS (pH 7.4), and fixed with cold methanol. The inguinal lymph node cells were then washed with cold PBS (pH 7.4), and then stained with cold PBS (pH 7.4) for 30 minutes at 4 ° C with an antibody recognizing pSTAT4 bound to APC, followed by FACS Calibur (flow cytometry). BD Bioscience) and Flow jo (Thermo Fisher Scientific). Each sample was analyzed by dot plot to compare the amount of pSTAT4 expressed in CD3 + CD8 + T cells. As a result, compared with mono-mIL-12-Fc, bi-mIL-12-Fc increased the expression of pSTAT4 when CD8 + T cells were activated in the groin lymph nodes of tumor-grafted mice.
- Figure 25 (D) is a result of measuring the ratio of CD8 + T cells expressing T-bet inhibiting the differentiation of memory cells in the groin lymph nodes 72 hours after one intraperitoneal administration of Figure 25 (C) by flow cytometry.
- Inguinal lymph node cells were stained with PE-cy5 or FITC-bound CD3 and CD8 antibody for 30 minutes at 4 ° C, washed with cold PBS (pH 7.4), and stained with transcription factor Foxp3 / Transcription.
- Cells were fixed and permeabilized using a Factor Staining Buffer Set (Thermo Fisher Scientific). Afterwards, the antibody recognizes T-bet conjugated with PE or APC, and then stained at 4 ° C. for 30 minutes, and then added a permeabilization buffer to FACS Calibur (BD Bioscience) and Flow jo (Thermo Fisher Scientific). ). Each sample was analyzed by dot plot to compare the proportion of CD3 + CD8 + T cells expressing T-bet.
- bi-mIL-12-Fc increased the expression of T-bet when CD8 + T cells were activated in the groin lymph nodes of mice transplanted with tumors. Therefore, the differentiation of CD8 + T cells into monolithic cells when bi-mIL-12-Fc at the same molar concentration as 1 ⁇ g IL-12 was observed in the peritumor lymph nodes of mice transplanted with tumors than mono-mIL-12-Fc. It was confirmed that the expression of pSTAT4 and T-bet was increased when CD8 + T cells were activated in the inguinal lymph nodes (tumor draining lymph nodes).
- spleen and groin lymph nodes were extracted from normal Balb / c mice, pulverized using a wire mesh in Petri dishes, and washed with 10 ml of medium containing 2% FBS. Thereafter, 1 ml of red blood cell lysis buffer was added to lyse red blood cells, and then washed with PBS to prepare a cell suspension. Lymphocytes were stained for 30 minutes at 4 ° C with antibodies bound to PE-binding CD8, washed with cold PBS (pH 7.4), and then combined with anti-PE microbeads (Miltenyi Biotec) for 15 minutes. Miltenyi Biotec) was used to isolate CD8 + T cells.
- pSTAT4 and T-bet were stained by the method of FIGS. 25 (C) and 25 (D), respectively, and analyzed by flow cytometry, FACS Calibur (BD Bioscience) and Flow jo (Thermo Fisher Scientific). Each sample was analyzed by dot plot to compare the amount of pSTAT4 or T-bet expressed in CD8 + T cells. As a result, when mono-mIL-12-Fc was cross-linked with an antibody that recognizes Fc, the CD8 + T cells were stimulated by two molecules of IL-12, similar to those treated with bi-mIL-12-Fc. As a result, the expression of pSTAT4 and T-bet was increased.
- mono-mIL-12-Fc induces less expression of pSTAT4 and T-bet in CD8 + T cells than bi-mIL-12-Fc so that CD8 + T cells have a memory effect.
- Differentiation into cells leads to differentiation into effect memory cells and central memory cells, so even at low concentrations (molar concentrations such as 0.5 ⁇ g IL-12), the tumors of mice transplanted with tumors can be removed to extend the lifespan of the mice. .
- bi-mIL-12-Fc induces the expression of pSTAT4 and T-bet in CD8 + T cells to differentiate into short-lived effect cells and to prevent differentiation into memory cells, thus molar concentrations such as mono-mIL-12-Fc
- molar concentrations such as mono-mIL-12-Fc
- the tumor was not completely removed from the transplanted mouse, and cytotoxic CD8 + T in the effector phase was directly administered at a higher concentration (molar concentration such as 2 ⁇ g IL-12).
- the cells must be expanded to remove the tumor.
- Heterodimeric Fc-fused protein according to the antibody heavy chain constant region according to the present invention by forming a protein complex of two or more subunits to mimic the physiologically active protein forms in nature, It can maintain the activity as it exists in nature, and also has the advantage that the half-life in the body of the bioactive protein can be significantly extended.
- heterodimeric-fusion protein heterodimeric Fc-fused protein
- the heterodimeric-fusion protein form according to the present invention has the advantage that it is easy to prepare a monovalent heterodimer-fusion protein without further purification process optimization.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (17)
- 항체(immunoglobulin) 중쇄불변부위 (Fc) 쌍의 제1 Fc 영역 및 제2 Fc 영역을 포함하고, A first Fc region and a second Fc region of an antibody (immunoglobulin) heavy chain constant region (Fc) pair,상기 제1 Fc 영역 및/또는 제2 Fc 영역의 N-말단 또는 C-말단 중 하나 이상의 말단에 생리활성 단백질의 서브유닛이 결합되어 있는 항체 중쇄불변부위 이종이중체-융합단백질(heterodimeric Fc-fused protein)에 있어서, Heteroodimeric Fc-fused antibody heavy chain constant region, in which a subunit of a physiologically active protein is bound to one or more of the N-terminus or C-terminus of the first Fc region and / or the second Fc region. protein)상기 생리활성 단백질은 2 이상의 서로 다른 서브유닛(subunit)으로 이루어져 있으며, 2 이상의 서로 다른 서브유닛(subunit)은 단백질 복합체(protein complex)를 형성하여 생리활성을 나타내는 것을 특징으로 하며,The bioactive protein is composed of two or more different subunits (subunit), the two or more different subunits (subunit) is characterized in that the protein complex (protein complex) to form a physiological activity,상기 제1 Fc 영역 및 제2 Fc 영역은 이종이중체(heterodimeric Fc)의 형성이 촉진되도록 CH3 도메인이 변이된 것임을 특징으로 하는 항체 중쇄불변부위 이종이중체-융합단백질(heterodimeric Fc-fused protein).The first Fc region and the second Fc region are heterologous antibody-heteroodimeric Fc-fused proteins, characterized in that the CH3 domain is mutated to promote the formation of heterodimeric Fc.
- 제1항에 있어서, The method of claim 1,상기 제1 Fc 영역 또는 제2 Fc 영역의 N-말단 또는 C-말단 중 어느 하나의 말단에만 생리활성 단백질의 서브유닛 중 하나가 결합되어 있고, 상기 생리활성 단백질의 나머지 서브유닛이 링커-매개된 형태로 상기 1 Fc 영역 또는 제2 Fc 영역의 N-말단 또는 C-말단 중 어느 하나의 말단에 결합된 생리활성 단백질의 서브유닛과 결합되어 있는 항체 중쇄불변부위 이종이중체-융합단백질.One of the subunits of the bioactive protein is bound to either the N-terminus or the C-terminus of the first Fc region or the second Fc region, and the remaining subunits of the bioactive protein are linker-mediated. The antibody heavy chain constant heterodimer-fusion protein, which is bound to a subunit of a bioactive protein bound to either the N-terminus or the C-terminus of the 1 Fc region or the second Fc region in the form.
- 제1항에 있어서, The method of claim 1,제1 Fc 영역 및 제2 Fc 영역의 N-말단 또는 C-말단 각각에 1 종의 생리활성 단백질을 구성하는 서로 다른 하나 이상의 서브유닛(subunit)이 각각 결합되어 있는 항체 중쇄불변부위 이종이중체-융합단백질.The antibody heavy chain constant region heterodimer, in which one or more different subunits constituting one bioactive protein is respectively bound to the N-terminus or C-terminus of the first Fc region and the second Fc region, respectively. Fusion proteins.
- 제1항에 있어서, The method of claim 1,서로 다른 서브유닛이 1 종의 단백질 복합체(protein complex)를 형성하여 활성을 나타내는 생리활성 단백질은 인터루킨 12 (IL-12), 인터루킨 23 (IL-23), 인터루킨 27 (IL-27), 인터루킨 35 (IL-35) 및 난포자극호르몬(FSH)로 이루어진 군으로부터 선택되는 것을 특징으로 하는 이종이중체-융합단백질.Physiologically active proteins in which different subunits form one protein complex and exhibit activity are interleukin 12 (IL-12), interleukin 23 (IL-23), interleukin 27 (IL-27), and interleukin 35 (IL-35) and follicle stimulating hormone (FSH) heterodimer-fusion protein, characterized in that it is selected from the group consisting of.
- 제4항에 있어서, The method of claim 4, wherein서로 다른 서브유닛이 1 종의 단백질 복합체(protein complex)를 형성하여 활성을 나타내는 생리활성 단백질은 인터루킨 12 (IL-12)인 것을 특징으로 하는 항체 중쇄불변부위 이종이중체-융합단백질.Biologically active heterozygote-fusion protein, characterized in that the physiologically active protein showing the activity by different subunits forming one protein complex (interleukin 12) (IL-12).
- 제5항에 있어서, The method of claim 5,상기 제1 Fc 영역 또는 제2 Fc 영역의 N-말단 또는 C-말단 중 어느 하나의 말단에만 인터루킨 12 (IL-12)의 p35 또는 p40 서브유닛이 결합되어 있고, 나머지 서브유닛이 링커-매개된 형태로 상기 1 Fc 영역 또는 제2 Fc 영역의 N-말단 또는 C-말단 중 어느 하나의 말단에 결합된 서브유닛과 결합되어 있는 항체 중쇄불변부위 이종이중체-융합단백질.The p35 or p40 subunit of interleukin 12 (IL-12) is bound to only one of the N-terminus or C-terminus of the first Fc region or the second Fc region, and the remaining subunits are linker-mediated. The antibody heavy chain constant heterodimer-fusion protein, which is bound to a subunit bound to either N-terminus or C-terminus of the 1 Fc region or the second Fc region in the form.
- 제5항에 있어서, The method of claim 5,제1 Fc 영역 및 제2 Fc 영역의 N-말단 또는 C-말단 각각에 인터루킨 12 (IL-12)의 p35 및 p40 서브유닛이 각각 결합되어 있는 항체 중쇄불변부위 이종이중체-융합단백질.An antibody heavy chain constant heterodimer-fusion protein wherein p35 and p40 subunits of interleukin 12 (IL-12) are respectively bound to the N-terminus or C-terminus of the first Fc region and the second Fc region.
- 제1항에 있어서, The method of claim 1,상기 제1 Fc 영역 및 제2 Fc 영역은 각각 인간 IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD 및 IgE로 이루어진 군으로부터 선택된 Fc 영역 유래인 것을 특징으로 하는 항체 중쇄불변부위 이종이중체-융합단백질.Wherein the first Fc region and the second Fc region are derived from an Fc region selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD, and IgE, respectively. protein.
- 제1항에 있어서, The method of claim 1,상기 제1 Fc 영역 및 제2 Fc 영역은 인간 IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD 및 IgE로 이루어진 완전한 항체(whole antibody) 형태에 포함되어 있는 것을 특징으로 하는 항체 중쇄불변부위 이종이중체-융합단백질.Wherein the first Fc region and the second Fc region are contained in a whole antibody form consisting of human IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD, and IgE. Sieve-fusion protein.
- 제1항에 있어서, The method of claim 1,상기 제1 Fc 영역 또는 제2 Fc 영역의 CH3 도메인의 변이는 다음의 군에서 선택된 하나 이상의 변이를 포함하는 것을 특징으로 하는 항체 중쇄불변부위 이종이중체-융합단백질. (단, 변이 위치는 EU index에 따름)The mutation of the CH3 domain of the first Fc region or the second Fc region comprises at least one mutation selected from the group of the antibody heavy chain constant heterodimer-fusion protein. (However, the mutation position is according to the EU index)(1) 제1 Fc 영역의 CH3 도메인의 K370 위치에서의 K370E, K370R, K370M, K370D 또는 K370H의 아미노산 잔기의 치환; (1) substitution of the amino acid residue of K370E, K370R, K370M, K370D or K370H at the K370 position of the CH3 domain of the first Fc region;(2) 제2 Fc 영역의 CH3 도메인의 E357 위치에서의 E357N, E357D, E357A, E357I, E357G 또는 E357M의 아미노산 잔기의 치환, 및 S364 위치에서의 치환은 S364T 또는 S364W의 아미노산 잔기의 치환;(2) substitution of the amino acid residues of E357N, E357D, E357A, E357I, E357G, or E357M at the E357 position of the CH3 domain of the second Fc region, and the substitution at the S364 position comprises a substitution of an amino acid residue of S364T or S364W;(3) 제1 Fc 영역의 CH3 도메인의 K409 위치에서의 K409W의 아미노산 잔기의 치환; 및(3) substitution of the amino acid residue of K409W at the K409 position of the CH3 domain of the first Fc region; And(4) 제2 Fc 영역의 CH3 도메인의 F405 위치에서의 F405T 아미노산 잔기의 치환, 및 D399 위치에서의 D399V의 아미노산 잔기의 치환. (4) substitution of the F405T amino acid residue at the F405 position of the CH3 domain of the second Fc region, and substitution of the amino acid residue of D399V at the D399 position.
- 제1항에 있어서, The method of claim 1,상기 제1 Fc 영역 또는 제2 Fc 영역의 CH3 도메인의 변이는 다음의 군에서 선택된 하나 이상의 변이를 포함하는 것을 특징으로 하는 항체 중쇄불변부위 이종이중체-융합단백질. (단, 변이 위치는 EU index에 따름)The mutation of the CH3 domain of the first Fc region or the second Fc region comprises at least one mutation selected from the group of the antibody heavy chain constant heterodimer-fusion protein. (However, the mutation position is according to the EU index)(1) 제1 Fc 영역의 CH3 도메인의 K360 위치에서의 K360E의 아미노산 잔기의 치환; (1) substitution of the amino acid residue of K360E at the K360 position of the CH3 domain of the first Fc region;(2) 제2 Fc 영역의 CH3 도메인의 E347 위치에서의 E347R의 아미노산 잔기의 치환; (2) substitution of the amino acid residue of E347R at the E347 position of the CH3 domain of the second Fc region;(3) 제1 Fc 영역의 CH3 도메인의 K409 위치에서의 K409W의 아미노산 잔기의 치환; (3) substitution of the amino acid residue of K409W at the K409 position of the CH3 domain of the first Fc region;(4) 제2 Fc 영역의 CH3 도메인의 F405 위치에서의 F405T 아미노산 잔기의 치환, 및 D399 위치에서의 D399V의 아미노산 잔기의 치환. (4) substitution of the F405T amino acid residue at the F405 position of the CH3 domain of the second Fc region, and substitution of the amino acid residue of D399V at the D399 position.
- 제10항 또는 제11항에 있어서, The method according to claim 10 or 11, wherein상기 제1 Fc 영역 및 제2 Fc 영역의 CH3 도메인 내에 하기의 결합을 추가로 포함하는 것을 특징으로 하는 이종이중체-융합단백질. (단, 상기 위치는 EU index에 따름)The heterodimer-fusion protein of claim 1, further comprising the following bonds in the CH3 domains of the first and second Fc regions. (However, the position is according to the EU index)(1) 제1 Fc 영역의 CH3 도메인 내 Y349 위치에 치환된 시스테인 (C); 및(1) cysteine (C) substituted at the Y349 position in the CH3 domain of the first Fc region; And(2) 제2 Fc 영역의 CH3 도메인 내 S354 위치에 치환된 시스테인 (C)의 결합.(2) binding of cysteine (C) substituted at the S354 position in the CH3 domain of the second Fc region.
- 제1항 내지 제12항 중 어느 한 항에 따른 항체 중쇄불변부위 이종이중체-융합단백질을 포함하는 약제학적 조성물. A pharmaceutical composition comprising the antibody heavy chain constant region heterodimer-fusion protein according to any one of claims 1 to 12.
- 제13항에 있어서, The method of claim 13,상기 항체 중쇄불변부위 이종이중체-융합단백질 내에 포함된 생리활성 단백질은 인터루킨 12 (IL-12)인 것을 특징으로 하는 약제학적 조성물. Pharmaceutical composition, characterized in that the bioactive protein contained in the antibody heavy chain constant region heterodimer-fusion protein is interleukin 12 (IL-12).
- 제14항에 있어서, The method of claim 14,암 치료를 위한 약제학적 조성물. Pharmaceutical compositions for the treatment of cancer.
- 제15항에 있어서, The method of claim 15,상기 암은 대장암, 흑생종, 유방암, 췌장암, 신장암, 전립선암, 난소암, 소장암, 식도암, 자궁경부암, 폐암, 림프종 및 혈액암으로 이루어진 군에서 선택되는 것을 특징으로 하는 약제학적 조성물. The cancer is a pharmaceutical composition, characterized in that selected from the group consisting of colon cancer, melanoma, breast cancer, pancreatic cancer, kidney cancer, prostate cancer, ovarian cancer, small intestine cancer, esophageal cancer, cervical cancer, lung cancer, lymphoma and hematologic cancer.
- 제15항에 있어서, The method of claim 15,다른 항암제와 병용 치료를 위한 약제학적 조성물. Pharmaceutical compositions for the combination treatment with other anticancer agents.
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780062851.0A CN110267977A (en) | 2016-08-10 | 2017-08-10 | Cell factor immunoglobulin Fc merges heterodimer and the pharmaceutical composition comprising it |
SG11201901071TA SG11201901071TA (en) | 2016-08-10 | 2017-08-10 | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
US16/323,839 US10696722B2 (en) | 2016-08-10 | 2017-08-10 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
EP17839824.4A EP3511340A4 (en) | 2016-08-10 | 2017-08-10 | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
MX2019001651A MX2019001651A (en) | 2016-08-10 | 2017-08-10 | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same. |
AU2017310163A AU2017310163B2 (en) | 2016-08-10 | 2017-08-10 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
CA3033475A CA3033475A1 (en) | 2016-08-10 | 2017-08-10 | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
BR112019002394-1A BR112019002394B1 (en) | 2016-08-10 | 2017-08-10 | HETERODIMERIC PROTEIN FLUTED WITH CF AND ITS USE |
JP2019506697A JP6993403B2 (en) | 2016-08-10 | 2017-08-10 | Heterodimer Fc fusion cytokine and pharmaceutical composition containing it |
ZA2019/00772A ZA201900772B (en) | 2016-08-10 | 2019-02-06 | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
US16/886,177 US11078249B2 (en) | 2016-08-10 | 2020-05-28 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
US16/886,184 US11692019B2 (en) | 2016-08-10 | 2020-05-28 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
AU2021273642A AU2021273642A1 (en) | 2016-08-10 | 2021-11-26 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
US18/323,124 US20230416325A1 (en) | 2016-08-10 | 2023-05-24 | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160101823 | 2016-08-10 | ||
KR10-2016-0101823 | 2016-08-10 | ||
KR1020170101594A KR102050463B1 (en) | 2016-08-10 | 2017-08-10 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
KR10-2017-0101594 | 2017-08-10 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/323,839 A-371-Of-International US10696722B2 (en) | 2016-08-10 | 2017-08-10 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
US16/886,177 Continuation US11078249B2 (en) | 2016-08-10 | 2020-05-28 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
US16/886,184 Division US11692019B2 (en) | 2016-08-10 | 2020-05-28 | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018030806A1 true WO2018030806A1 (en) | 2018-02-15 |
Family
ID=61163082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/008676 WO2018030806A1 (en) | 2016-08-10 | 2017-08-10 | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018030806A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110088124A (en) * | 2016-09-02 | 2019-08-02 | 高丽大学校产学协力团 | The Il-21 (heterodimer Fc merges IL-21) merged with immunoglobulin heavy chain constant region heterodimer (heterodimer Fc) and the pharmaceutical composition comprising it |
CN110396133A (en) * | 2018-04-25 | 2019-11-01 | 中国科学院生物物理研究所 | It is a kind of using interleukin 12 as the fusion protein type prodrug of active constituent |
WO2020086758A1 (en) * | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
WO2020072821A3 (en) * | 2018-10-03 | 2020-06-18 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
US11078249B2 (en) | 2016-08-10 | 2021-08-03 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
WO2021246720A1 (en) * | 2020-06-01 | 2021-12-09 | 머스트바이오 주식회사 | Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor |
US11471490B2 (en) | 2017-07-03 | 2022-10-18 | Torque Therapeutics, Inc. | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof |
US11851466B2 (en) | 2019-10-03 | 2023-12-26 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
RU2819097C2 (en) * | 2018-10-03 | 2024-05-14 | Ксенкор, Инк. | Il-12 heterodimeric fc fusion proteins |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100015089A1 (en) * | 1997-12-08 | 2010-01-21 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US7695936B2 (en) | 1995-03-01 | 2010-04-13 | Genentech, Inc. | Knobs and holes heteromeric polypeptides |
WO2014084607A1 (en) * | 2012-11-27 | 2014-06-05 | 아주대학교산학협력단 | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
WO2014145907A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Targeting t cells with heterodimeric proteins |
KR20150008012A (en) * | 2013-07-12 | 2015-01-21 | 한미약품 주식회사 | Conjugate of biologically active polypeptide monomer and immunoglobulin Fc fragment with reduced receptor-mediated clearance, and the method for preparing the same |
KR20150142181A (en) | 2014-06-11 | 2015-12-22 | 주식회사 엘지화학 | Manufacturing method of vinyl chloride based resin |
-
2017
- 2017-08-10 WO PCT/KR2017/008676 patent/WO2018030806A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7695936B2 (en) | 1995-03-01 | 2010-04-13 | Genentech, Inc. | Knobs and holes heteromeric polypeptides |
US20100015089A1 (en) * | 1997-12-08 | 2010-01-21 | Merck Patent Gmbh | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
WO2014084607A1 (en) * | 2012-11-27 | 2014-06-05 | 아주대학교산학협력단 | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
KR101522954B1 (en) | 2012-11-27 | 2015-05-27 | 아주대학교산학협력단 | CH3 domain mutant pairs for the high yield formation of heterodimeric Fc of antibody, method of production and use thereof |
WO2014145907A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Targeting t cells with heterodimeric proteins |
KR20150008012A (en) * | 2013-07-12 | 2015-01-21 | 한미약품 주식회사 | Conjugate of biologically active polypeptide monomer and immunoglobulin Fc fragment with reduced receptor-mediated clearance, and the method for preparing the same |
KR20150142181A (en) | 2014-06-11 | 2015-12-22 | 주식회사 엘지화학 | Manufacturing method of vinyl chloride based resin |
Non-Patent Citations (3)
Title |
---|
HA, JI-HEE ET AL.: "Immunoglobulin Fc Heterodimer Platform Technology: from Design to Applications in Therapeutic Antibodies and Proteins", FRONTIERS IN IMMUNOLOGY, vol. 7, 6 October 2016 (2016-10-06), pages 1 - 16, XP055377975, DOI: doi:10.3389/fimmu.2016.00394 * |
LOW, S. C. ET AL.: "Oral and Pulmonary Delivery of FSH-Fc Fusion Proteins via Neonatal Fc Receptor-mediated Transcytosis", HUMAN REPRODUCTION, vol. 20, no. 7, 2005, pages 1805 - 1813, XP002455704, DOI: doi:10.1093/humrep/deh896 * |
See also references of EP3511340A4 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11692019B2 (en) | 2016-08-10 | 2023-07-04 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
US11078249B2 (en) | 2016-08-10 | 2021-08-03 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
CN110088124A (en) * | 2016-09-02 | 2019-08-02 | 高丽大学校产学协力团 | The Il-21 (heterodimer Fc merges IL-21) merged with immunoglobulin heavy chain constant region heterodimer (heterodimer Fc) and the pharmaceutical composition comprising it |
US11471490B2 (en) | 2017-07-03 | 2022-10-18 | Torque Therapeutics, Inc. | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof |
CN112638938A (en) * | 2018-04-25 | 2021-04-09 | 免疫靶向有限公司 | Interleukin 12 fusion proteins and compositions and methods of treatment thereof |
WO2019209965A3 (en) * | 2018-04-25 | 2019-12-05 | Immune Targeting Inc. | Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof |
CN110396133B (en) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | Fusion protein type prodrug with interleukin 12 as active component |
JP2021521822A (en) * | 2018-04-25 | 2021-08-30 | イミューン ターゲティング インク. | Interleukin 12 fusion protein and composition, and their therapeutic methods |
CN110396133A (en) * | 2018-04-25 | 2019-11-01 | 中国科学院生物物理研究所 | It is a kind of using interleukin 12 as the fusion protein type prodrug of active constituent |
RU2819097C2 (en) * | 2018-10-03 | 2024-05-14 | Ксенкор, Инк. | Il-12 heterodimeric fc fusion proteins |
WO2020072821A3 (en) * | 2018-10-03 | 2020-06-18 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
US11655277B2 (en) | 2018-10-03 | 2023-05-23 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
CN113286808A (en) * | 2018-10-23 | 2021-08-20 | 蜻蜓疗法股份有限公司 | Heterodimeric Fc fusion proteins |
JP2022505871A (en) * | 2018-10-23 | 2022-01-14 | ドラゴンフライ セラピューティクス, インコーポレイテッド | Heterodimer FC fusion protein |
US11787864B2 (en) | 2018-10-23 | 2023-10-17 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
WO2020086758A1 (en) * | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
US11851466B2 (en) | 2019-10-03 | 2023-12-26 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
WO2021246720A1 (en) * | 2020-06-01 | 2021-12-09 | 머스트바이오 주식회사 | Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor |
WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018030806A1 (en) | Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same | |
WO2020060122A1 (en) | Fusion protein comprising il-2 protein and cd80 protein, and use thereof | |
WO2015133817A1 (en) | Monoclonal antibody specifically recognizing b-cell lymphoma cells and use thereof | |
WO2017023138A1 (en) | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed | |
WO2015058573A1 (en) | Monoclonal antibody for antagonizing and inhibiting binding of programmed death (pd-1) to ligand thereof and coding sequence and use thereof | |
WO2020050667A1 (en) | Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor | |
WO2017065484A1 (en) | Method for producing antibody ch3 domain heterodimeric mutant pair using yeast mating and ch3 mutant pair produced thereby | |
WO2014025198A2 (en) | Lfa3 mutant, fusion protein in which target-specific polypeptides are connected to the mutant or lfa3 cd2 binding region, and use thereof | |
WO2021107689A1 (en) | Pharmaceutical composition for treatment of cancer, comprising immune checkpoint inhibitor and fusion protein including il-2 protein and cd80 protein | |
WO2011142514A1 (en) | Composition containing pias3 as an active ingredient for preventing or treating cancer or immune disease | |
WO2018026248A1 (en) | Novel antibody against programmed cell death protein (pd-1), and use thereof | |
WO2021158073A1 (en) | Fusion antibody for presenting antigen-derived t cell antigen epitope or peptide containing same on cell surface, and composition comprising same | |
WO2023277361A1 (en) | Mesothelin-specific antibodies and use thereof | |
WO2022177394A1 (en) | Bispecific single domain antibody to pd-l1 and cd47 and use thereof | |
WO2022025638A1 (en) | Chimeric antigen receptor (car) t cell stabilizing immune synapse | |
WO2016199964A1 (en) | Antibody specifically binding to isolated vimentin-derived peptide, or binding fragment of peptide | |
WO2019045477A1 (en) | Composition for preventing and treating skin disease comprising substance specifically binding to vimentin-derived peptide | |
WO2022035200A1 (en) | Fusion protein comprising il-12 and anti-cd20 antibody and use thereof | |
WO2022145739A1 (en) | Humanized antibody specific for cd22 and chimeric antigen receptor using the same | |
WO2021071319A1 (en) | Multispecific fusion protein and use thereof | |
WO2018026249A1 (en) | Antibody against programmed death-ligand 1 (pd-l1), and use thereof | |
WO2020204305A1 (en) | Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof | |
WO2020138868A1 (en) | Type 1 interferon neutralizing fc-fusion protein and use thereof | |
WO2021162394A1 (en) | Chimeric antigen receptor targeting b-cell maturation antigen and use thereof | |
WO2023121254A1 (en) | Interleukin-2 fusion protein, method for preparing same, and pharmaceutical composition comprising same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17839824 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019506697 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3033475 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019002394 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017310163 Country of ref document: AU Date of ref document: 20170810 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017839824 Country of ref document: EP Effective date: 20190311 |
|
ENP | Entry into the national phase |
Ref document number: 112019002394 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190206 |